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Abstract: 
 
The ubiquitin-like with PHD and ring finger domains 1 (UHRF1) is a DNA binding protein, 
involved in epigenetic regulation. UHRF1 expression varies in different cancers, and its role in 
pancreatic ductal adenocarcinoma (PDAC) is unknown. PDAC is a devastating disease with an 
overall 5-year survival rate of less than 5 %. Here we report that UHRF1 is frequently 
overexpressed in PDAC and negatively regulates Keap1, an important component of the Nrf2-
mediated cellular stress response pathway. UHRF1 was expressed in 114 of 132 (86%) 
pancreatic tumours, was associated with larger tumour size (p= 0.02) and had higher expression 
in tumours compared to matched preneoplastic (PanIN) lesions (n=9). UHRF1 expression varied 
at different phases of the cell cycle with a peak level at G2/M. Moreover, siRNA-mediated 
depletion of UHRF1 was associated with a G2/M phase block and induced apoptosis. UHRF1 
protein expression levels varied in different PDAC cell lines and reflected the DNA methylation 
levels in examined sequences. UHRF1 knockdown reduced global DNA methylation in LINE-1 
and Alu-V repetitive elements and tumour suppressor-specific (p16Ink4a and RASSF1) promoter 
methylation. Combining UHRF1 knockdown with 5-aza-deoxycytidine treatment resulted in 
restoration of P16 levels compared to controls siRNA samples. KEAP1 expression loss was 
previously reported in ~70 % of PDAC cases. Here we established that the Keap1 promoter is 
hypermethylated in pancreatic cancer cells. UHRF1 knockdown was accompanied by a 
reduction in Keap1 promoter methylation, restoration of KEAP1 protein, loss of NRF2 protein 
and corresponding loss of NRF2 downstream gene expression. We showed strong evidence that 
Keap1 expression is regulated by its promoter methylation, as KEAP1 expression was restored 
following 5-aza-deoxycytidine treatment. In PDAC tumour specimens (n=124), an inverse 
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relationship between UHRF1 and KEAP1 expression was observed (p=0.002). In summary, we 
have shown a role for UHRF1 in pancreatic cancer growth and promoter methylation. 
Moreover, we have discovered an important function for UHRF1 in controlling KEAP1 
expression and consequently regulating the KEAP1/NRF2 stress response pathway. 
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1 Introduction: 
1.1 Hallmarks of cancer: 
Genetic mutations or alterations in the expression of tumour suppressor genes (TSGs) or 
oncogenes underlie cancer development. These genes are important for normal cell 
proliferation, differentiation, and homeostasis. Mutations in, or alteration of expression of TSGs 
most often result in loss of functional proteins, whereas mutation or overexpression of 
oncogenes result in gain of function and promote tumorigenesis [1]. Although over 200 
different types of human cancer have been identified, they share common features. At least six 
alterations in a cell’s physiology, independent of its environment, are required for a cell to 
become malignant. This includes self-sufficiency from growth factor signals, insensitivity to anti-
growth signals, evasion of apoptosis, limitless replicative potential, angiogenesis within the 
tumour mass and tissue invasion/metastasis [2]. Another four cancer hallmarks have been 
latterly added to the list including genome instability, inflammation [3], abnormal cellular 
metabolism and evading immune destruction [4]. 
1.2 Introduction to pancreatic cancer: 
Pancreatic cancer is almost always a lethal disease with a very poor survival rate. The Cancer 
Research UK (CRUK) statistics in 2010 reported that 157,000 cases were diagnosed with cancer 
in the UK, and 5 % of these cases were pancreatic cancer (www.cancerresearchuk.org). Thus, 
pancreatic cancer is rated as the 10th most common cancer. It is the 5th most common cause of 
death in the UK, with 5 year survival observed in less than 5 % of diagnosed patients. Pancreatic 
cancer affects males and females equally and most patients diagnosed are aged 60 years old or 
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above. People develop pancreatic cancer without identifiable symptoms; therefore, most 
pancreatic cancer cases are diagnosed in very late stages of the disease and frequently have 
metastasis at the time of diagnosis [5]. Many risk factors play roles in the development of 
pancreatic cancer, such as age, smoking, excess weight, alcohol and diet. Several medical 
conditions have been linked to pancreatic cancer development including diabetes, pancreatitis, 
family history and genetic mutations [6]. 
Pancreatic cancers mostly develop in the head of the pancreas and less commonly in the body 
or in the tail. Moreover, there are different types of pancreatic cancer, either exocrine or 
endocrine. Almost 80 % of pancreatic cancer cases can be classified as exocrine, which primarily 
develop tumour masses in the duct system of the exocrine pancreas leading to ductal 
adenocarcinoma (PDAC). The other exocrine cancers are; cystic tumours, cancer of the acinar 
cells and sarcoma of the pancreas. Endocrine pancreatic cancer is very rare and includes 
gastrinomas, insulinomas, somatostatinomas, VIPomas and glucogonomas 
(www.cancerresearchuk.org). In 2010 the World Health Organization (WHO) published a new 
edition for pancreatic cancer classification, subtypes and grades [7]. Pancreatic cancers are 
known to be highly resistant to chemotherapy treatment, although chemotherapy has been 
shown to benefit patients in both the advanced and adjuvant settings [8-11]. Currently surgery 
offers the best hope of cure. However, only a minority of patients (approximately 20 %) are 
eligible for surgery [12, 13]. 
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1.3 Pathophysiology of pancreatic cancer: 
The normal pancreas is composed of 2 main cell types which have endocrine (hormones) and 
exocrine (digestive enzymes) functions. Hormones maintain the level of blood sugar and 
digestive enzymes are released to the duodenum through the ductal system of the pancreas for 
food digestion and pH maintenance [14]. As the main endocrine function of the pancreas is to 
regulate the glucose level in the blood, 80 % of pancreatic cancer patients are diagnosed with 
diabetes. It is still unclear if pancreatic cancer causes diabetes or diabetes promotes pancreatic 
cancer development  [15]. Several clinical and pathological changes arise in the organ as a 
result of cancer development, and are mainly solid or cystic [16]. The most common pancreatic 
neoplasm is pancreatic ductal adenocarcinoma, which causes obstruction in the ductal system 
of the pancreas as well as the bile duct. Obstruction of the bile duct causes jaundice which is 
one of the complications developed by pancreatic cancer patients. Also steatorrhoea, an excess 
of fat in stools, may result due to duct obstruction. Patients with metastasis to the liver may 
have enlarged liver. As most pancreatic cancer develop in the head of the pancreas, most 
patients develop back pain [17].  
1.4 Clinical trials for PDAC treatment: 
In general terms, the main approaches for cancer treatment are surgical removal of the tumour 
mass and irradiation and chemotherapy, depending on the tumour type and stage of the 
disease. Recently immunotherapy has been proposed as an important cancer treatment [18]. 
Chemotherapy may be used to improve symptoms and prolong survival of cancer patients; it is 
also needed following surgery to reduce the risk of recurrent tumour growth. In clinical trials, 
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combinations of chemotherapy and surgery or radiotherapy have clearly demonstrated 
improvement in survival compared to surgery or radiotherapy alone in several types of cancers 
[19]. Generally anti-cancer drugs target distinct pathways to induce tumor cell death. Therefore 
the cell’s response to the anti- cancer drugs differs according to the disturbed pathway. Anti-
cancer drugs often target cells by interfering with DNA synthesis and replication within the cell 
cycle [20]. Many drugs are under validation in clinical trials, to minimize their side effects, and 
to improve outcome. Examples of chemotherapeutic drugs and their mechanisms of action are 
reviewed elsewhere [4, 13]. The efficacy of these chemotherapeutic drugs can be significantly 
reduced due to genetic alteration resulting in drug resistance [20]. Clinical trials have shown 
survival advantages when several drugs are combined instead of exposing patients to a single 
specific drug as a first line therapy. Gemcitabine combined with capecitabine (GEM-CAP) 
showed survival advantages compared to gemcitabine (GEM) alone, in advanced and metastatic 
pancreatic cancer [9]. FOLFIRINOX is a combination of oxaliplatin, irinotecan, fluorouracil (FU) 
and leucovorin that resulted in survival benefits in patients with metastatic pancreatic cancer 
compared to gemcitabine [21]. New biological therapies are undergoing clinical trials in mouse 
models and in humans. One such example is vandetanib, a tyrosine kinases inhibitor that 
inhibits cell growth [22]. This drug is currently being evaluated in the VIP trial, the aim of which 
is to compare GEM treatment alone to GEM combined with vandetanib in advanced pancreatic 
cancer patients. The Phase III European Study Group for Pancreatic Cancer-3 (ESPAC-3) trial 
showed that GEM and FU with folic acid were equally effective in the adjuvant setting. Based on 
ESPAC-3 the most efficient drugs used for pancreatic cancer treatment are GEM, FU and folic 
acid. In addition, patients in ESPAC-3 who received full six cycles of treatment after surgery 
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showed improved survival compared to patients who received less than six cycles of treatment. 
Also there was no significant difference in survival outcome between patients treated early or 
later after surgery. This study suggests that delaying the start time for chemotherapeutic 
treatment allows the pancreatic cancer patients to recover from surgery, as patients who feel 
stronger are more likely to complete the full six cycles of treatment [10]. 
1.5 Genetics of pancreatic cancer: 
The pancreatic cancer tumour mass is multi-cellular, comprising a combination of pancreatic 
cancer cells, pancreatic cancer stem cells and tumour stroma. The tumour stroma itself 
contains many cell types. A variety of different cancer pathways are affected in this tumour 
type [23]. A progression model for pancreatic cancer has been derived, in which the cancer is 
shown to develop through different stages. Changes in benign epithelial cells and the 
development of precursor lesions have been documented. The most common pancreatic 
cancer precursor lesions are the pancreatic intraepithelial neoplasia (PanINs), which arise with 
many morphological, histological and genetic or epigenetic changes (Figure 1-1) [24]. 
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Figure 1-1 : Stages of pancreatic cancer development. The normal pancreatic ductal cell 
transforms to cancer cells through intermediate stages of PanINs. This figure is taken from [24] 
with the authors’ permission. 
 
 
 
Pancreatic cancer development has been associated with over sixty genetic alterations, most of 
which are point mutations [8]. These alterations result in disruption of 12 cellular pathways; 
apoptosis, DNA damage, cell cycle transition at G1/S, Hedgehog signaling, homophilic cell 
adhesion, integrin signaling, c-Jun N-terminal kinase signaling, KRAS signaling, regulation of 
invasion, small GTPase-dependent signaling, TGF-β signaling and Wnt/Notch signaling. Not all of 
the 12 pathways are disrupted in every pancreatic cancer and every pathway is linked to a gene 
mutation [8]. Genomic instability in pancreatic cancer occurs early during tumorigenesis, as 
over 50 % of genomic rearrangements are detected in both the primary tumour and in 
metastases [25]. 
The K-RAS oncogene is the most common mutationally activated oncogene in pancreatic cancer 
and is activated in 90 % of cases. It plays a role in several signaling pathways that involve cell 
growth [5, 23, 26-29]. K-Ras mutations result in K-RAS GTPase activation which mediates 
stimulation of several signaling pathways, such as the RAF-mitogen-activated protein kinase, 
Normal PanIN Tumour 
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phosphoinositide-3-kinase (PI3K) and RalGDS pathways (Figure 1-2 ). The continuous activation 
of K-Ras plays a role in the cell growth, proliferation and survival [30]. 
 
Figure 1-2. RAS signaling pathway. RAS regulates different pathways involved in cell growth. 
This figure is taken from [31] without permission. 
 
The most commonly inactivated TSG in pancreatic cancer is the cyclin dependent kinase 
inhibitor 2A gene or Inhibitor of CDK4 (CDKN2A/p16INK4a), which encodes the P16 protein. P16 
plays a role in the initiation and progression of pancreatic cancer. Other TSGs are inactivated in 
pancreatic cancer, such as TP53 and SMAD4. These genetic alterations start early in PDAC and 
are detected in the precursor lesions [5, 23, 26-29]. 
 
 
                                                                                                                                                 Chapter 1: Introduction 
27 
 
1.6 Epigenetic changes in pancreatic cancer: 
In addition to the well-characterized genetic changes, epigenetic changes play a fundamental 
role in pancreatic cancer development and progression [32]. Amongst these, DNA methylation 
is a well-known epigenetic mechanism which influences pancreatic cancer through the silencing 
of TSG promoters. The CDKN2A gene [33] and several other genes in pancreatic cancer cells 
have been activated following treatment with demethylation drugs [34]. UHRF1 (ubiquitin-like, 
containing PHD and RING finger domains 1), contributes to the maintenance of DNA 
methylation by recruiting DNMT1 to its hemimethylated DNA substrate [35]. The enzyme DNA 
methyltransferase 1 (DNMT1) is considered responsible for maintaining methylation patterns of 
methylated cytosine residues from the parent strand of DNA to the newly synthesised daughter 
strand [36]. A recent study analyzed proteins from pancreatic cancer specimens and normal 
pancreas in order to identify new protein markers for pancreatic cancer. This study reported 
over-expression of UHRF1 in pancreatic cancer but not in normal pancreas [37]. No descriptive 
or functional studies of UHRF1 in this cancer type have been published. In this thesis we have 
investigated some of UHRF1’s roles in pancreatic cancer. 
1.7 Ubiquitin-like, containing PHD and RING finger domains (UHRF1): 
UHRF1, also known as ICBP90, is a DNA binding and multi-domain protein [38, 39].  UHRF1 is a 
member of the UHRF family that comprises 4 members: UHRF1, UHRF2, UHRF3 and UHRF4. The 
functions of UHRF4 have not been reported, but it is listed in the gene database (gene bank). 
The structures of UHRF3 and UHRF4 are different from UHRF1 [40]. UHRF2 has the same 
structure as UHRF1 but it has a different function. It is involved in cell cycle regulation and it has 
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been reported to interact with UHRF1 [41]. The UHRF1 protein contains different domains in its 
structure; the ubiquitin-like domain (UBL), 1st Tudor domain, 2nd Tudor domain, Plant Homeo 
Domain (PHD), Pre-PHD, Set and Ring associated domain (SRA) and the really interesting new 
gene domain (RING) [42] (Figure 1-3). 
 
Figure 1-3: UHRF1 protein structure. UHRF1 domains; UBL: ubiquitin-like domain, 1st Tudor 
domain, 2nd Tudor domain, PHD: Plant Homeo domain, Pre-PHD, SRA: Set and Ring associated 
domain and RING: really interesting new gene domain. 
 
UHRF1 has a critical role in cell growth and proliferation [38, 40]. UHRF1 is involved in 
epigenetic regulation during cell division, including DNA methylation maintenance and histone 
modification. In our study we focused on the role of UHRF1 in DNA methylation maintenance in 
pancreatic cancer cells. UHRF1 binds to the hemimethylated DNA via its SRA domain, mutations 
in the SRA domain results in loss of UHRF1 ability to bind to the DNA [43, 44]. Given that 
histone-modification is an important mechanism for regulation of gene expression, UHRF1 
recruits histone methyltransferase to the histone H3 tail [45, 46]. UHRF1 recognizes the H3 tail 
by either its PHD domain [47, 48] or by the action of both tudor and PHD domains at the same 
time [49]. The RING domain is responsible for the ubiquitin E3 ligase activity of UHRF1, which 
reveals the importance of UHRF1 in cell regulation and growth [38]. It is still unknown if UHRF1 
domains act in a dependent or independent manner from each other [50]. UHRF1 stability is 
maintained by protein-protein interaction with ubiquitin specific processing protease 7 (USP7), 
also known herpes virus-associated ubiquitin specific processing protease 7 (HAUSP), an 
UBL PHD SRA RING1st 2nd
Tudor
Pre-
PHD
UHRF1
a
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important protein required to activate DNMT1. UHRF1 and DNMT1 form a complex with USP7 
in-order to successfully methylate the DNA [51]. A recent study showed that UHRF1 
phosphorylation in the M-phase, results in USP7-UHRF1 complex dissociation, leading to a 
reduction of UHRF1 steady-state level. This study suggests that maintained levels of UHRF1 are 
important for regulating cellular proliferation [52]. UHRF1 stability under normal conditions and 
in response to DNA damage is controlled by SCFβ-TrCP with ubiquitin E3 ligase activity [53]. 
UHRF1 in mouse is called Np95 and its endogenous expression in normal T-cells shows highest 
levels at S phase and lowest levels at G2/M, while in tumour T-cells its expression is not 
changed during cell cycle [39, 54]. UHRF1 is overexpressed in several types of human cancers 
[55] such as bladder [56, 57], breast [58, 59], colorectal [60, 61] prostate [62] and lung cancer 
[63, 64]. UHRF1 overexpression induced cancer transformation in hepatic cells [65]. UHRF1 
overexpression was observed in pancreatic cancer, but the study lacked any analysis of the 
functional role of UHRF1 in pancreatic cancer [37]. 
1.7.1 The mechanism of ubiquitin (UB) enzymatic activity: 
 
The ubiquitination of proteins is an important process for regulating degradation and 
determining the half-life and expression levels of proteins in the cell. This targeting for 
degradation depends on a number of enzymes classed as E1, E2 and E3, with each acting to 
form a cascade reaction. E1 acts as the first activating enzyme in the ubiquitination pathway, 
activating UB for subsequent transferral to E2 enzymes. E2s act as carriers or conjugating 
enzymes that mediate E3 action on the targeted protein. E3 UB ligases recognise specific 
proteins and facilitate ubiquitin conjugation to then target the protein to the 26S proteasome 
for degradation [66]. 
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1.8 Cell cycle regulation and apoptosis: 
1.8.1 Cell cycle regulation: 
 
The cell cycle is the process where cells undergo replication through four different phases 
including, G1, S, G2 and M; this process is controlled by a complex of many activators or 
inhibitors. The G1 phase, known as the cell growth phase, is where the cell increases in size. 
During G1 cells produce crucial proteins for use in subsequent phases of the cell cycle. S phase 
follows where new DNA synthesis takes place and the cell duplicates its DNA contents. The cell 
prepares for division during G2 then forms two new cells during M phase, splitting the DNA and 
cellular components in half. Following M phase, the cells reenters the cycle at G1/G0 [67]. The 
cell cycle is regulated by enzymes essential for progression beyond specific checkpoints, in 
particular cyclin dependent kinases (Cdks), cyclins and cyclin dependent kinase inhibitors (CKIs). 
These are known to regulate transcription, epigenetic regulation, metabolism, stem cell self-
renewal neuronal function and spermatogenesis [67, 68]. Cdks are produced in G1, and activate 
DNA replication resulting in initiation of the G1/S transition and activation of downstream 
proteins that are involved in later events in the cell cycle. Losing control of cell division, 
especially at the transition from G1 to S phase, results in cancer development [69, 70]. The 
members of the cyclin protein family include cyclin E, cyclin D, cyclin A and cyclin B. Cyclin E and 
D interact with cdK 2 to control G1 and are important for retinoblastoma protein Rb/E2F 
transcription, which is essential for cell differentiation and growth [68]. Rb/E2F transcription 
factors are required for cell entry into S phase; furthermore, Rb/E2F proteins have been found 
to be overexpressed in most types of cancer [70]. Cyclin A also interacts with cdk2 and cdk1 to 
control S phase, while cyclin B controls progression through M phase [68]. Cyclin B is important 
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for survival and proliferation of cancer cells [71]. Most of the cyclins are produced during the 
cell cycle, but cyclin D is regulated by the Ras-signaling pathways after extracellular signal-
regulated kinase (ERK) activation [70]. Defects in cyclin expression affect cell cycle progression 
and result in decreased cell viability; downregulation of cyclin B leads to reduced cyclin A 
expression, S phase delay and apoptosis [72]. Cyclin E cleavage is associated with apoptosis in 
tumour cells [73]. 
1.8.2 Apoptosis: 
Apoptosis is programmed cell death which takes place in normal adult tissue regulation and 
plays a role in normal embryonic development [74]. Apoptosis is regulated by a family of 
proteases called Caspases (cysteine-dependent aspartate-specific proteases) that are involved 
in the activation and transduction of apoptotic induction. Caspases are divided into two main 
groups based on their function. The initiator caspases (caspases 2, 8, 9 and 10) are responsible 
for activating the activator caspase cascade. Activator caspase (caspases 3, 6 and 7) activation 
results in cleavage of many structural proteins such as actin, fodrin, lamin and gelsolin, leading 
to nuclear and cellular morphology alteration. Activator caspase substrates also include 
members of cellular DNA repair mechanisms including poly ADP-ribose polymerase (PARP) and 
DNA-PK [75-77]. Caspase 3 cleavage results in the induction of caspases 2 and 6 which drive the 
cell to complete apoptosis [78]. 
1.8.3 The role of UHRF1 in cell cycle regulation and apoptosis: 
 
UHRF1 depletion from different cancer cells, including breast and colorectal, results in 
activation of the DNA damage response pathway, cell cycle arrest at G2/M phase and apoptosis 
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induction. UHRF1 causes cell cycle arrest and apoptosis in an independent manner to p53 
expression [79]. UHRF1-induced apoptosis involves activation of caspase 8 and the downstream 
effector caspase 3; evidenced by loss of apoptotic induction by UHRF1 depletion in caspase 8 
knockdown cells [79]. On the other hand, it has been reported that UHRF1 depletion causes cell 
cycle arrest at G1 phase in Hela cells [80]. In lung cancer, UHRF1 plays an important role in cell 
cycle regulation; its depletion from human non-small lung cancer cells resulted in either G1 cell 
cycle arrest or G2/M phase arrest [38]. The expression level of UHRF1 through the cell cycle is 
not clear, as in one study UHRF1 showed maintained  levels through all cell cycle phases [81] 
and in another report UHRF1 showed reduction in its steady levels in M phase proliferation 
[52]. This study suggests that maintained levels of UHRF1 are important for regulating cellular 
proliferation [52]. Thus, UHRF1 appears to play an important role in cell cycle progression and 
its depletion results in cell cycle obstruction. In the current study, we examined the role of 
UHRF1 in cell cycle regulation utilising pancreatic cancer as a model. 
1.9 DNA Methylation: 
DNA methylation is one of the epigenetic alterations that cause cancer development. 
Epigenetic modifications of the DNA structure cause changes in gene expression, rather than 
changes in the primary coding DNA sequence. These changes are heritable and can be reversed 
with treatment. In DNA, methylation occurs in cytosine residues followed by guanine in the 
DNA sequence (CpG). In normal cells, DNA methylation is an organised process and the addition 
of a methyl group to the CpG sites is not random. DNA methylation occurs at specific sites on 
the genome, including CpG rich regions or islands in the promoter region within the DNA 
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sequence, which result in gene inactivation. Other sites of DNA methylation include CpG-
containing repetitive DNA sequences for the maintenance of DNA stability. Hypomethylation of 
these sites has been linked to cancer development (Figure 1-4) [82]. 
 
Figure 1-4. A schematic drawing presents the DNA methylation status in normal and cancer 
cells. In normal cells, gene promoters are non-methylated while the repetitive sequences are 
heavily methylated. In cancer cells, gene promoters are silenced by DNA methylation 
(hypermethylation) and the repetitive elements are hypomethylated. 
 
Silencing of many TSGs through promoter methylation and subsequent loss of protein function 
has been reported in several types of cancers. In normal cells DNA methylation plays an 
important role in regulating gene expression, for example, the random X inactivation in females 
[83]. Moreover, DNA methylation is an important process for normal embryonic development 
and maintaining chromosomal stability [84]. DNA methylation levels vary during the cell cycle 
with the lowest levels detected during G1 that subsequently increase during S phase [85]. DNA 
methylation is catalysed by enzymes called DNMTs. As mentioned previously above, UHRF1 
contributes to the maintenance of DNA methylation by recruiting DNMT1 to its 
hemimethylated DNA substrate [35]. The DNA methylation mechanism is regulated by DNMT1 
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through the addition of a methyl group to carbon five in the cytosine ring to form 5-
methylcytosine, using S-adenosyl-methionine (SAM) as a methyl donor as shown in (Figure 1-5) 
[86]. 
 
Figure 1-5. The DNA methylation mechanism. DNMT1 adds a methyl group to the carbon 
number 5 in the cytosine ring to form 5-methylcytosine using S-adenosyl-methionine (SAM) as a 
methyl donor. 
 
UHRF1 recruits the DNMT1 to the hemi-methylated DNA and together they form a complex 
with other important proteins, which are required for DNA replication and cell proliferation, to 
allow successful methylation and inheritance of the methylated DNA to the newly produced 
daughter cells during cell division (Figure 1-6) [87]. UHRF1 has been found to interact with 
DNMT1 protein within the S phase of the cell cycle, during DNA synthesis [43]. 
 
S-adenosyl-L-methionine S-adenosyl-L-homocysteine
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Figure 1-6. UHRF1 binds hemi-methylated DNA and recruits DNMT1 to allow full DNA 
methylation. 
 
 
 
1.10 The role of UHRF1 in DNA methylation: 
UHRF1 plays an important role in DNA damage repair, epigenetic regulation and DNA 
replication. One mechanism by which UHRF1 recruits DNMT1 onto the hemi-methylated DNA 
sequence has been proposed [88]. Briefly, UHRF1 recognizes the hemi-methylated cytosine in 
the CpG sites through its SRA domain, forming SRA-DNA complexes. The SRA binding flips the 
methyl-cytosine base outside of the DNA double strand, allowing UHRF1 to bind DNMT1. 
Following DNMT1 binding, the non-methylated cytosine is flipped from the other side of the 
DNA helix to be targeted by DNMT1. DNMT1 adds a methyl group to the targeted cytosine 
resulting in a fully methylated CpG site (Figure 1-7). DNA methylation maintenance mechanism 
takes place in S phase of the cell cycle [81]. 
 
UHRF1
UHRF1
Methylated CpG Un-Methylated CpG
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Figure 1-7. DNA methylation maintenance by UHRF1, the Flipping model. UHRF1 recognises 
hemi-methylated DNA by its SRA domain. The methylated cytosine is flipped to the outside of 
the DNA helix. Following DNMT1 binding to UHRF1, the non-methylated cytosine is flipped to 
the other side of the DNA helix and is targeted by DNMT1. This figure is taken [88] without 
permission. 
 
 
 
1.10.1 DNA methylation in cancer: 
Global changes in the epigenetic landscape are one of the hallmarks of cancer. Many cancers 
exhibit changes in their DNA methylation pattern compared to benign cells. DNA 
hypermethylation refers to an increase in methylation, while the loss of DNA methylation level 
is referred to as DNA hypomethylation. Both hypermethylation and hypomethylation have been 
reported in several cancers [89]. DNA hypermethylation in gene-specific promoters leads to the 
blockade of gene transcription. Promoter silencing of TSGs by DNA hypermethylation is a 
common epigenetic development in cancer, and has been reported for CDKN2A, CDKN2B, 
MGMT, MLH1, BRCA1, CDH1, CDH13 and DAPK1. Loss of TSG function disturbs many pathways 
in the cell, including cell cycle regulation, DNA repair and apoptosis as well as tumour 
metastasis [89, 90]. DNA methylation is a reversible mechanism that occurs early in cancer 
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development. Epigenetic therapy or de-methylating agents can reverse DNA methylation and 
prevent cancer progression [91]. 
DNA hypomethylation of repetitive sequences affects genomic instability and can cause 
chromosomal re-arrangement or translocation. DNA hypomethylation of silenced oncogenes 
results in oncogenic reactivation and promotes carcinogenesis [89, 90]. In pancreatic cancer the 
gene promoters of the CDKN2A [92], RASSF1 [93] and other genes [94] are highly methylated 
unlike in normal cells. 
1.10.2 DNA methylation therapy: 
The most common de-methylation agent used in cancer treatment is 5-aza-deoxycytidine. This 
drug consists of a ring analogue of the pyrimidine nucleoside cytidine, in which a nitrogen atom 
replaces the carbon group number 5 which interferes with DNMT activity. The drug specifically 
binds to DNA and blocks DNMT binding, promoting de-methylation and re-expression of 
silenced genes [83] (Figure 1-8). The free DNMT1 molecules are degraded by ubiquitination 
thus reducing the DNA methylation level [95]. 
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Figure 1-8. The mechanism of action of 5-aza-deoxycytydine. (a). DNMT1 adds a methyl group 
to the cytosine ring. A methyl group is donated by SAM (adenosyl-methionine) (b) 5-aza-
deoxycytidine adds a nitrogen atom to carbon number 5 which blocks DNMT1 activity. 
 
 
5-aza-deoxycytidine restores gene expression by either de-methylation dependent or 
independent mechanisms [96]. Treatments with 5-aza-deoxycytidine to reactivate silenced 
genes, regulate apoptosis and increase sensitivity to radiotherapy have been used in clinical 
trials in prostate cancer patients [97]. DNMT1 overexpression plays a role in cancer progression 
by increasing the methylation level and inactivation of certain genes [98]. 
1.10.3 DNA methylation measurement protocols:  
Different methods are available for the measurement of DNA methylation, including 
methylation specific PCR (MSP) (Taqman and Sybr-green), microarray expression profiling, 
restriction landmark genomic scanning, CHIP-on-chip and pyrosequencing [99]. Most of these 
techniques only allow for the analysis of specific CpGs or are time- and cost-intensive, but 
Pyrosequencing overcomes these limitations [100]. In our study, we used the Pyrosequencing 
a
b
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technique to examine DNA methylation status. Only a small quantity of DNA is needed for each 
run, so this technique preserves DNA samples from clinical specimens [101]. One advantage of 
pyrosequencing lies in its simplicity combined with the accuracy of measurements of DNA 
methylation levels for each CpG in the targeted sequences. Briefly, the protocol begins with 
DNA bisulfate treatment followed by polymerase chain reaction (PCR) leading to 
pyrosequencing (Figure 1-9). 
 
Figure 1-9. DNA sequencing results following bisulfite treatment. The 5th nucleotide in the 
original DNA sequence is a methylated cytosine, which was not converted to thymine following 
CT conversion by bisulfite treatment, while the unmethylated cytosines in the original DNA 
sequence were completely converted into uracil and complemented with thymine following 
PCR. 
 
The methylation level is calculated by analysing the ratio of C to T in the CpG site [102]. The 
amplified DNA contains one biotinylated strand that serves as a pyrosequencing template. This 
template and the sequencing primers are incubated with DNA polymerase, ATP sulfurylase, 
luciferase, apyrase, substrates adenosine 5' phosphosulfate (APS) and luciferin. Following 
primer annealing, the primers are extended by DNA polymerase which catalyzes the addition of 
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complementary deoxyribonucleotide triphosphate (dNTP). This reaction resulted in 
pyrophosphatase (PPi) release in equivalent amount of each added nucleotide (Figure 1-10). 
 
 
Figure 1-10: The DNA is amplified by PCR and the biotinylated sequence serves as a 
pyrosequencing template. Following primer annealing the enzyme DNA polymerase facilitates 
the addition of complementary nucleotides to extent the primer sequence and the PPi is 
released in each reaction. 
 
The unused dNTPs or ATPs are degraded by an enzyme called apyrase. At the time when 
degradation at each step is finished, the next set of nucleotides is added for further sequence 
extension (Figure 1-11). 
                                                                                                                                                 Chapter 1: Introduction 
41 
 
 
Figure 1-11. Apyrase degrades unused dNTPs or ATPs after each nucleotide addition. 
 
DNA polymerase requires dATP for its activity, and for this initial step the source of dATPs in the 
reaction is deoxyadenosine alfa-thio triphosphate (dATPαS). Later in the process, the enzyme 
luciferase does not recognize dATPαS but instead uses ATP produced by an enzyme called 
sulfurylase that converts PPi to ATP in the presence of adenosine 5' phosphosulfate (APS). 
Luciferase then mediates the conversion of luciferin to oxyluciferin, resulting in light generation 
as explained in Figure 1-12a. The amount of generated light is equivalent to ATP used in the 
reaction. The light is detected by a charge coupled device (CCD) camera provided in the 
pyrosequencing machine and visualised as a peak (Figure 1-12 a). The nucleotide addition 
reaction is then repeated, resulting in elongation of the complementary DNA strand and the 
generation of further peaks. The nucleotides detected by the signal peak raw data output 
produces a pyrogram (Figure 1-12 b). The global DNA methylation level of repetitive elements 
LINE1 is widely used as a standard reference of whole genomic methylation when determining 
new methylation measurement methods or improving existing methods [103-105]. 
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Figure 1-12. Raw data generation in the pyrosequencing reaction. (a). Luciferase uses ATP 
which is produced by sulfurylase that converts PPi to ATP. Luciferase mediates the conversion 
of luciferin to oxyluciferin, resulting in light generation. The amount of generated light is 
equivalent to ATP used in the reaction. The light is then detected as a peak by a CCD camera. 
(b). Raw data output in the program at the end of the run. 
 
1.10.4 Global DNA hypomethylation: 
CpG sites in DNA repetitive elements are highly methylated in normal mammalian cells, to 
maintain DNA stability. Global de-methylation of these sequences including transposable 
elements is an early event in cancer development [90]. Repetitive genomic DNA sequences 
a
b
a
b
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include long interspersed nuclear elements (LINEs), short interspersed nuclear elements (SINEs) 
and satellite repeats. Transposable elements form 45 % of the human genome and are 
classified into DNA transposons and retrotransposons. DNA transposons are inactive in the 
human genome and are inserted into the DNA sequence by a cut and paste mechanism. 
Retrotransposons are transcribed into an RNA intermediate followed by amplification through a 
reverse transcriptase mechanism and insertion into new regions in the human genome. 
Retrotransposons are grouped into long terminal repeats retrotransposable elements (LTRs) 
and non-LTRs. LTRs have limited activity in the human genome and containing long-terminal 
repeats at both ends of their DNA sequence, while non-LTRs are active and contain poly-A 
sequences at the 3’ end of their sequence. The well-known non-LTR elements in the human 
genome are LINE1 and Alu-V elements. Almost 30% of the human genome is made of these 
elements, and their activity has been implicated in several diseases [106]. 
1.10.4.1 LINE1 and Alu-V elements: 
LINE1 elements form approximately 17 % of the human genome. The full length of LINE1 is 
nearly 6 kbp [106]. LINE1 sequences contain a 5’ untranslated region (5’UTR), two open reading 
frames (ORF) that produce two proteins needed for retrotransposition, and a 3’ UTR. Each ORF 
has its own activity; ORF1 has an RNA binding site and facilitates DNA amplification during the 
retrotransposition process, while ORF2 has endonuclease (EN) and reverse transcriptase (RT) 
binding sites. The EN domain causes DNA cleavage at specific sites identified by 5’ TTTT AA 3’ 
DNA sequences. The mechanism of how LINE1 retrotransposes is not fully understood [107]. 
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Alu-V elements comprise about 11 % of the human genome, at a full length of 300 bp and do 
not code for any protein. It is thought that Alu-V is linked to chromosomal abnormalities and 
genomic stability [108]. 
1.10.4.2 LINE1 and Alu-V elements in cancer: 
 
LINE1 elements have been widely examined in human cells and in particular how their 
hypomethylation can cause genomic instability and chromosomal breaks [107]. LINE1 
hypomethylation is detected in several cancer types, including early neoplastic stages of cancer 
development [109]. Genomic instability due to LINE1 hypomethylation was detected in early 
stages of urothelial carcinoma [110]. LINE1 hypomethylation was also detected in different 
tumours, compared to matched normal tissues from the same studied organs. It has been 
reported that LINE1 methylation is tissue-specific in different cancers, including, breast, colon, 
lung, head and neck, bladder, esophagus, liver, prostate and stomach. The hypomethylation 
level in colonic cancer was greater in advanced stages when compared to dysplastic polyps and 
normal epithelial tissues [105]. Hepatocellular carcinoma patients have been shown to have 
higher LINE1 hypomethylation levels in their leukocyte DNA [111]. In breast cancer, LINE1 and 
Alu-V elements were hypomethylated in tumours compared to normal tissue and white blood 
cells (WBC) DNA [112]. A recent pilot study evaluated the methylation changes in whole blood 
with a view to identifying markers for the detection of pancreatic tumors. LINE-1 and Alu 
repeats were slightly less methylated compared to control blood [113]. In this study, we 
focused on global DNA methylation regulation by UHRF1 in pancreatic cancer cell lines. 
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1.11 Tumour suppressor gene hypermethylation: 
DNA hypermethylation of TSG promoters is a common epigenetic change in different cancers as 
described in section 1.10.1. In pancreatic cancer CDKN2A [92], RASSF1 [93] are frequently 
hypermethylated. Since both of these genes form important components of this thesis, they are 
described below. 
1.11.1 Cyclin dependent kinase inhibitor 2A (CDKN2A): 
CDKN2A is the most frequently inactivated TSG in pancreatic cancer. This gene encodes the 
p16INK4A protein which plays an important role in normal cell cycle regulation by inhibiting cyclin 
dependent kinases (CDK4 and CDK6) and arresting the cell cycle in late G1 phase. p16INK4A 
protein function is lost in 95% of pancreatic cancer cases.  CDKN2A inactivation is an early event 
in pancreatic cancer and can be detected in PanINs [29]. p16INK4A inactivation by DNA 
methylation has been reported in several cancers including head and neck squamous carcinoma 
[114], hepatocellular carcinoma [115], gallbladder cancer [116] and pancreatic cancer [92]. It 
has been demonstrated that demethylation agents such as 5-aza-deoxycytidine can restore 
p16INK4A protein expression in cancer cells [20]. 
1.11.2 Ras association domain family 1 (RASSF1): 
 
Ras association domain family 1 is a member of the RASSF family. The RASSF family consists of 
ten members and is known to play an important role in cell cycle control and apoptosis. A 
recent review has shown that eight of ten members are hypermethylated in various cancers 
[117]. RASSF1 has been reported to be hypermethylated in pancreatic and other cancers [93, 
112]. In different mouse model studies, RASSF1 plays a role in cell growth, cell cycle regulation, 
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cell migration and apoptosis [117]. RASSF1 silencing in pancreatic cancer has been shown to be 
inversely correlated with K-Ras activation [93]. 
1.12 The KEAP1 / NRF2 pathway: 
K-RAS activation was shown to promote tumorigenesis in pancreatic cancer by activating the 
KEAP1 (Kelch-like ECH-associated protein 1)/ NRF2 (Nuclear factor erythroid 2-related factor 2) 
pathway vivo [118]. The KEAP1 / NRF2 pathway protects normal cells from chemical or 
oxidative stress. KEAP1 interacts with the transcription factor NRF2, directing it for 
ubiquitination and proteasomal degradation. Disruption of the interaction between NRF2 and 
KEAP1 occurs under numerous cellular stress conditions mechanism [119], and results in 
stabilization and nuclear accumulation of NRF2. Subsequently, nuclear NRF2 interacts with 
antioxidant response elements (AREs) to promote transcription of genes encoding antioxidant 
proteins, detoxification enzymes and xenobiotic transporters [120]. The nuclear accumulation 
of NRF2 is thought to protect the cell from chemotherapeutic agents and facilitate cancer 
progression [120]. 
1.12.1 NRF2 normal function and structure: 
NRF2 plays a major role in cellular homeostasis, differentiation, proliferation, and 
inflammation. In normal cells, NRF2 is a central regulator of antioxidant enzymes and is 
responsible for protecting the internal cellular environment whenever the cell is exposed to 
chemical or oxidative stress. NRF2 plays a major role in cellular homeostasis, differentiation, 
proliferation, and inflammation [121]. NRF2 mediates the induction of target genes such as 
heme oxygenase-1 (HO-1) and NAD(P)H:quinone oxidoreductase 1 (NQO1) to protect against 
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the inflammatory response in human monocytes [122]. Also it has been reported that NRF2 
plays a role in the suppression of pro-inflammatory signaling pathways [123]. Therefore, NRF2 
is an important target for anti-inflammatory drugs [124, 125]. NRF2 also plays a role in cellular 
proliferation [126] and tumour development [127]. In pancreatic cancer NRF2 has been 
reported to increase cell proliferation [128]. NRF2 also regulates the activation of DNA repair 
pathways in response to exposure to reactive chemical species [129]. NRF2 generally is a key 
regulator of phase II drug detoxification and antioxidant enzymes or transporters, which can be 
upregulated to inhibit xenobiotic toxicity [130]. In a mouse model, it has been reported that the 
expression of multidrug resistance-associated protein transporters is dependent on NRF2 [131]. 
As a result of these and other functions, dysfunction of NRF2 enhances susceptibility to the 
onset of various diseases. A summary of the pathways that NRF2 regulates is shown in Figure 
1-13. 
 
Figure 1-13. A schematic drawing summarising NRF2 responses.  
 
 
NRF2 protein structure as shown in Figure 1-14 contains 6 different NRF2-ECH-homology (Neh) 
domains. Neh1 is a DNA binding domain, Neh2 is the KEAP1 binding domain, Neh 3-5 domains 
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are responsible for transactivation of NRF2 and Neh6 domain is responsible for NRF2 
degradation [119, 132]. The Neh2 domain contains 2 important motifs, the low-affinity DLG 
motif and the high-affinity ETGE motif, this domain is recognised by KEAP1, the repressor of 
NRF2 [133]. 
  
 
Figure 1-14. A schematic representation of NRF2 protein structure. 
 
 
 
1.12.2 KEAP1 normal function and structure: 
 
NRF2 activity is mainly regulated by KEAP1 by direct interaction or through an indirect 
mechanism [119]. In normal cells, NRF2 interacts with KEAP1 in the cytoplasm and regulates 
NRF2 levels by ubiquitination [133]. A detailed study showed that KEAP1 recruits NRF2 by the 
ETGE motif and the DLG motif is required for ubiutination signaling initiation [134]. In a Keap1 
deficient mouse model Nrf2 was found to accumulate in the nucleus [135]. KEAP1 has been 
identified as a substrate-specific adaptor protein of Cul3-based ubiquitin E3 ligase, to target 
NRF2 for proteasomal degradation, while under oxidative stress conditions this mechanism is 
inhibited [136, 137]. KEAP1 protein contains different domains as shown in Figure 1-15, 
including, broad-complex-tramtrack and bric-a-brac (BTB) domain at the N-terminal end, 
intervening linker domain (IVR), and the double glycine/Kelch repeats at the C-terminal end 
[119]. The BTB domain binds Cul3 protein and is responsible for NRF2 inhibition, with each Cul3 
ligase binding to two KEAP1 proteins [119, 137]. The C-terminal Kelch repeats facilitate NRF2 
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binding. The IVR is responsible for transmitting signals that affect the ability of the Kelch 
domain to bind NRF2 and maintain NRF2 stability [138], as it contains reactive cysteine residues 
that act as sensors for electrophilic and oxidative stress. The IVR domain is rich with cysteine 
residues [119] but two in particular are important for the maintenance of NRF2 basal level, 
namely Cys 273 and Cys 288 [133].  
 
 
 
Figure 1-15. A schematic representation of KEAP1 protein structure. 
 
1.12.3 KEAP1/NRF2 pathway regulation mechanisms: 
In normal cells, KEAP1 traps NRF2 in the cytoplasm and directs it for ubiquitination and 
proteasomal degradation. NRF2 is released from KEAP1 following exposure to a chemical or 
oxidative stress, and results in translocation of NRF2 to the nucleus and stimulation of its 
downstream target genes [136]. Following exposure to oxidative stress, modifications occur in 
the cysteine residues of KEAP1 that disturb its binding to the DLG and ETGE motifs of NRF2. As a 
result, NRF2 is not targeted for KEAP1-dependent ubiquitination and accumulates in the 
nucleus [133] . The activation of NRF2 takes place following signaling by KEAP1 as it is the 
primary oxidant sensor in this pathway, however NRF2 itself may contain oxidant sensors that 
cause its activation and nuclear translocation. For example, phosphorylation of NRF2 at serine 
40 leads to its activation and dissociation from KEAP1 [121].  This mechanism is summarized in 
Figure 1-16. 
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Figure 1-16. A schematic drawing depicting the KEAP1/NRF2 regulatory mechanism. In normal 
conditions KEAP1 and NRF2 complexes are located in the cytoplasm where KEAP1 negatively 
regulates NRF2 through ubiquitination and proteasomal degradation. While under oxidative 
stress, NRF2 dissociates from KEAP1 and translocates to the nucleus to activate downstream 
genes. 
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Downstream targets of NRF2 include antioxidant proteins, xenobiotic transporters and phase II 
drug metabolism enzymes [119]. The best known Nrf2 inducer is sulforaphane (SFN), which 
reacts with Cys 151 of KEAP1 and inhibits its activity, allowing nuclear translocation of Nrf2 and 
activation of antioxidant response elements (ARE) [139]. Cys 151 of KEAP1 is needed for the 
posttranslational modifications of KEAP1 that stimulates oxidative stress [129]. Activation of the 
KEAP1/NRF2 pathway results in the stimulation of several enzymes. Briefly, the most common 
targets of Nrf2 are phase II enzymes, such as NADPH quinone oxidoreductase (NQO1) and 
glutamate-cysteine ligase catalytic (GCLC), redox-active proteins such as heme oxygenase (HO-
1), and other enzymes [126, 140]. NRF2 also regulates the induction of cytochrome P450 
isoform 2A5 (CYP2A5), a member of the cytochrome P450 superfamily [141]. Moreover, 
CYP2A5 is the first identified P450 gene that is regulated by NRF2 under stress conditions [142]. 
Another study has suggested a different mechanism of KEAP1/NRF2 interaction referred to as 
the shuttling mechanism. Briefly, in normal cells, KEAP1 and NRF2 are located in the cytoplasm, 
where both are regulated by ubiquitination. When the cell is exposed to oxidative to oxidative 
or chemical stress, KEAP1 provides transportation of NRF2 to the nucleus, KEAP1 then returns 
to the cytoplasm without NRF2 or remains in the nucleus and activates the ARE genes as a 
complex, by a mechanism that is not yet understood [143]. This dynamic shuttling mechanism 
increases NRF2 stability and prevents NRF2 ubiquitination by KEAP1 in the nucleus [144]. NRF2 
is regulated by either KEAP1-dependant or KEAP1-independent mechanisms, where other 
proteins regulate its activity [119]. Other KEAP1-independent regulators of NRF2 function 
include mitogen-activated protein kinases (MAPK), phosphatidylinositol-3 kinase and protein 
kinase C  [121]. It has also been reported that KEAP1 is an ARE-dependent gene. KEAP1 protein 
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expression is down-regulated in both NRF2 positive and NRF2 negative cells as the antioxidant 
response take place [145].  
1.12.4 KEAP1/NRF2 pathway in cancer: 
 
Besides the protection that NRF2 gives to normal cells, it is also thought to have a pathological 
role in cancer. Here NRF2 has a dual role in that its downstream genes are overexpressed in 
tumours, assisting neoplastic transformation, whilst also protecting the cells against 
chemotherapy resulting in longer cell survival [146]. Phase II enzymes are a battery of 
important detoxifying proteins, which play a role in cell protection against mutagens. The 
expression of Phase II enzymes is not only disturbed in cancers, but also results in the 
occurrence of other diseases [147]. NRF2 deficiency leads to defects in cell proliferation and 
greatly enhances the cell’s sensitivity to oxidant-induced cell death [148]. The damage resulting 
in tissues due to oxidative stress is proportional to the severity of the stress and NRF2 
activation [149]. KEAP1 inactivation by gene mutation or loss of heterozygosity in cancer cells 
results in prolonged activation of NRF2 protein expression and its downstream genes, 
tumorigenesis and chemoresistance. The expression level of NRF2 is also correlated with 
resistance to several drugs [146]. Mutations in the reactive cysteine residues result in loss of 
function of KEAP1 [150]. In lung cancer patients with mutation in the recognition sites of DLG or 
ETGE motifs, NRF2 overexpression and resistance to chemotherapeutic treatments have been 
reported [127]. Inhibiting NRF2 and NRF2-dependent proteasome activity in pancreatic cancer 
resulted in improved response to anticancer drugs. Loss of KEAP1 protein due to promoter 
hypermethylation has been reported in several cancer types, including prostate, lung [151-155] 
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and colorectal cancer [147]. Thus, an emerging mechanism has been reported in cancer where 
the KEAP1/NRF2 pathway is regulated by methylation of the KEAP1 gene promoter. 
1.12.5 KEAP1/NRF2 pathway in pancreatic cancer: 
 
The KEAP1/NRF2 pathway is active in pancreatic cancer. NRF2 is up-regulated in pancreatic 
cancer cell lines and tissues, and its depletion by small interfering RNA (siRNA) decreases 
cellular proliferation and reduces resistance to different anticancer therapies (GEM, FU and 
cisplatin). The NRF2 gene in pancreatic cancer has no known mutations, while KEAP1 gene has 
been shown to contain synonymous mutations. One study has reported dysregulation of the 
KEAP1/NRF2 pathway in pancreatic cancer cells, while no significant correlations were found 
between KEAP1 expression and NRF2 in tissue specimens [128]. The oncogene K-RAS, which is 
commonly activated in pancreatic cancer, is also thought to regulate NRF2 expression levels in 
pancreatic cancer cells. Its depletion causes a decrease in NRF2 mRNA levels and an increase in 
reactive oxygen species (ROS) which can promote tumorigenesis. Thus, the continuous increase 
in NRF2 mRNA levels by K-Ras oncogene activation results in increased cellular protection and 
provides a cell survival advantage and resistance to apoptosis [118]. 
KEAP1 dysfunction due to its promoter hypermethylation has been reported in prostate, lung 
[151-155] and colorectal cancer [147]. In pancreatic cancer the KEAP1/NRF2 pathway is 
dysregulated and the KEAP1 gene has been examined for point mutations. The KEAP1 gene has 
no mutations in our pancreatic cancer cell lines [128], but the methylation status of its 
promoter in pancreatic cancer has not been examined. Accordingly, it is possible that DNA 
methylation controls KEAP1 expression in pancreatic cancer and this is a focal point of the 
investigation presented here. Additionally, it is notable that DNA methylation is regulated by 
                                                                                                                                                 Chapter 1: Introduction 
54 
 
UHRF1, which was shown by our group to be overexpressed in pancreatic cancer specimens but 
not in normal pancreas [37], and as this study nor other studies reported the functional role of 
UHRF1 in pancreatic cancer, the work presented here has evaluated UHRF1 expression and 
function in this type of cancer and its effect on DNA methylation status, including frequently 
methylated TSGs and the KEAP1 promoter. 
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2 Aims and objectives: 
 
The role of UHRF1 in pancreatic cancer has not previously been reported. In this study we aimed: 
• To characterize UHRF1 expression in pancreatic cancer cell lines and patient samples. 
• To examine UHRF1 function in pancreatic cancer cells. 
• To determine UHRF1’s role in the DNA methylation status in pancreatic cancer cells. 
• To determine if the KEAP1 promoter is methylated in pancreatic cancer, and whether 
UHRF1 regulates its methylation. 
To address these aims, this study had a number of objectives. 
Specific objectives included: 
•  To measure UHRF1 protein expression levels in different pancreatic cancer cell lines and 
in pancreatic cancer tissue using a tissue micro-array.  
•  To investigate UHRF1’s functional role in cell cycle regulation, proliferation and 
apoptosis in pancreatic cancer cells.  
• To measure the global DNA methylation levels in pancreatic cancer cells and assess the 
impact of alteration of UHRF1 expression levels on the DNA methylation levels. 
• To investigate the KEAP1 promoter methylation status in pancreatic cancer cells, and 
examine the associations of UHRF1 and Keap1 regulation. 
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3 Materials and methods: 
3.1 Tissue samples: 
A pancreatic ductal adenocarcinoma tissue microarray (TMA) was obtained from the Liverpool 
Cancer Tissue Bank, Department of Pathology, University of Liverpool. In general, 4 TMA 
sections with a total number of 132 cases were used in this study of UHRF1 expression in 
pancreatic cancer patients. Another 4 TMA sections with a total number of 124 samples from 
the same pancreatic cancer patients were used for KEAP1 scoring (Appendix 1). The TMAs were 
5 μm in thickness, paraffin embedded sections containing matched duplicate non-malignant 
and malignant cores. The TMAs also contain cores of normal colon, sarcoma, kidney and liver 
tissues used for orientation. Pancreatic cancer sections, with a total number 32, were used for 
UHRF1 antibody optimization and validation. 
3.2 Cell line maintenance: 
Pancreatic ductal adenocarcinoma cell lines, MiaPaca-2, CFpac-1, Panc-1, Suit-2 and BxPc-3 
(Table 1), were all maintained in RPMI medium supplemented with 10% Fetal Bovine Serum 
(FBS) (Sigma), 100 U/mL penicillin (Sigma), 100 ug/mL streptomycin (Sigma) and 2 nM L-
Glutmamine (Sigma). Cells were grown in vented T75 cell culture flasks (Nunc, NY) at 37 ⁰C in a 
5% CO2 incubator, sub-cultured when they reached 80 % confluence and the flasks were 
replaced every 2 weeks. All the cell lines were genotyped prior to use in this thesis. Genotyping 
was performed using gDNA from each cell line and the PowerPlex-16 HS system (Promega) was 
used to amplify the DNA fragments according to the manufacturer’s instructions. Detection of 
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the amplified fragments was performed using Genetic Analyzer (3130- Applied Biosystem) and 
GeneMapper software (Version 4.0) as described in [128].   
 
Cell line Established by Source of tumour cells 
MiaPaca-2 Yunis (USA) Primary tumour 
CFpac-1 R.A. Shoumacher (USA) Liver metastasis 
Panc-1 M. Lieber (USA) Primary tumour 
Suit-2 T. Iwamura (Japan) Liver metastasis 
BxPc-3 M.H. Tan Primary tumour 
Table 1:  Anatomical site of origin of pancreatic ductal adenocarcinoma cell lines. 
 
 
3.3 Freezing and thawing of cells stocks: 
Approximately 2 X106 pelleted cells were resuspended in 1 mL freezing medium (70 % RPMI 
medium (Sigma, 1640), 10 % dimethyl sulfoxide (DMSO) (Sigma) and 20 % FBS) and transferred 
to 1 mL screw caped cryo-vials (Nunc™, cat: 375418) followed by storage for 2 h at -80 ⁰C and 
then transferred to -140 ⁰C liquid nitrogen. 
3.4 Culturing cells from frozen stocks: 
Cells were carefully defrosted in a 37 ⁰C water-bath, centrifuged at 100 g for 5 min and then 
resuspended and washed with PBS to remove any remaining DMSO. Cells were pelleted from 
the PBS and resuspended in 1 mL pre-warmed medium followed by transfer into a culture flask 
containing 20 mL culture medium. 
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3.5 Western blot analysis: 
3.5.1 Protein lysate preparation: 
Harvested cells were washed with PBS. Then approximately 100 - 300 µL of ice cold Tris-SDS 
lysis buffer (10 % 1 M Tris-HCl pH 6.8, 20 % of 10 % sodium dodecyl sulfate (SDS), 70 % dH2O)  
or RIPA buffer (2 % 1 M Tris, 5 % 3 M NaCl, 0.5 % SDS, 1 % IGEPAL CA 630 (Sigma, 13021), 0.2 % 
0.5 M EDTA, pH 8, 91.3 % dH2O) and a freshly added tablet of complete mini EDTA-free 
protease inhibitor cocktail (Roche, cat: 11 836 170 001), was added to the cells followed by 
incubation overnight in –20 ⁰ C and subsequent disruption by sonication with 30 % intensity for 
5 sec. Protein lysates were clarified by centrifugation at 10,000 g at 4 ⁰C for 10 min. Clear 
lysates were aliquoted into 20 µg and stored at -20 ⁰C for short term storage (up to 1 month) 
and at - 80 ⁰C for long term storage. 
3.5.2 BCA Protein Assay: 
Quantification of total protein concentration was determined by Pierce bicinchoninic acid (BCA) 
protein assay for every lysate sample, following the manufacturer’s instructions (Thermo 
Scientific, 23225). Briefly, 50 µL of sample was added to 1 mL of working solution and incubated 
for 2 h at room temperature and the protein concentration was measured using a 
spectrophotometer at 562 nm with reference to a standard curve created by using known 
Bovine Serum Albumin concentrations (BSA). 
3.5.3 Protein sample preparation: 
Total protein lysate (20 μg) was mixed with 5 X sample loading buffer (10 % SDS, 50 % glycerol 
(BDH laboratory supplies), 300 mM Tris-HCl pH 6.8, 0.05 % Bromophenol Blue (Sigma), and 1M 
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dithiothreitol (DTT) (Sigma) freshly added) to reach final concentration of 1 X loading buffer. 
Samples were denatured at 95 ⁰C for 15 min prior to loading on an SDS-PAGE gel. 
3.5.4 Gel electrophoresis and protein detection: 
Equal quantities of denatured protein (20 µg/sample) and a molecular weight marker were 
loaded and separated on pre-casted Mini-PROTEAN TGX Any-KD Gels (BIO-RAD, 456-9034) for 
25 min at 200 volts using 1 X SDS running buffer (0.3 % trisma base, 1.44 % glycine, 0. 1 % g SDS 
(Sigma)). Samples were transferred during 7 min from the polyacrylamide gels onto positively 
charged membranes (0.2 µm PVDF (BIO-RAD, 170-4156)) using Bio-Rad turbo transfer 
apparatus according to the manufacturer’s instructions. The membranes were then blocked 
with 5 % non-fat milk (Bio-Rad) phosphate buffered saline + 0.04 % tween 20 (PBST) for 1 h at 
room temperature followed by overnight incubation at 4°C in with the appropriate primary 
antibody (Table 2) diluted in 5 % milk/PBST. Membranes were then washed with PBST for 1h (4 
X 15 min) and incubated with conjugated secondary antibody in 5 % milk/ PBST (Table 2) for 1 h 
at room temperature. Membranes were then washed with PBST for 1h (4 X 15 min). The 
protein bands were visualized with enhanced chemiluminescence ECL detection buffer 
(PerKinElmer) and signals were detected on sensitive x-ray films. This protocol was described in 
[128]. 
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Antibody  Species  Dilution  Supplier and Catalog number 
UHRF1 Mouse 1:1000 abcam, ab57083 
UHRF1 Mouse 1:1000 Santa Cruz, sc-136264 
KEAP1 Goat 1:1000 Santa Cruz, sc-15246 
NRF2  Rabbit 1:1000 abcam, ab137550 
P16 Mouse 1:500 Santa Cruz, sc373695 
Caspase 3 Mouse 1:1000 abcam, ab13847 
Cyclin A Rabbit 1:2000 Santa Cruz, sc751 
Cyclin B Mouse 1:2000 Santa Cruz, H-433 
Cyclin E Mouse  1:2000 Santa Cruz, sc248 
NQO1 Goat  1:3000 Abcam, ab2346 
GCLC Rabbit 1:3000 Abcam, ab53179 
HO-1 Rabbit  1:3000 Abcam, ab13243 
CYP2A5 Chicken  1:3000  Dr. Ian Copple,  
University of Liverpool 
β-actin Mouse 1:20,000 Sigma, A5441   
Polyclonal anti-mouse HRP Goat 1:3000 Dako, P 0447 
Polyclonal anti-rabbit -HRP Goat 1:3000 Dako, P 0448 
Polyclonal anti- Goat -HRP Rabbit  1:3000 Dako, P 0449 
Polyclonal anti- chicken -HRP Rabbit 1:5000 Sigma, A9046 
Table 2: Primary and secondary antibodies used for immuno-blotting. 
 
3.6 siRNA transfection: 
Cells were transfected using lipofectamine 2000 (Invitrogen, cat: 11668-019) in antibiotic-free 
medium according to the manufacturer’s instructions and as described in [128]. Briefly, cells 
were seeded in 6 well plates (Corning Incorporated 3516, Sterile) and allowed to grow 
overnight to reach 40 % confluence. At this time, 30 nM siRNA (Table 3 and Table 4) in 200 µL of 
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Opti-MEM, were added to 200 µL of Opti-MEM containing transfection solution and incubated 
at room temperature for 20-30 min then added drop-wise to the cells. At least 2 different 
control siRNAs were used in each experiment including the Non-targeting siRNA pool control 1 
(Thermo Scientific Dharmacon, cat: D-001206-13-20), RISC-free siRNA (Thermo Scientific 
Dharmacon, siGENOME® control siRNA, cat: D-001220-01-20), Scrambled siRNA negative 
control and Off-target siRNA  (Thermo Scientific Dharmacon, cat: D-001810-01-20). Following 
transfection, cells were incubated for 72 h at 37 °C before harvesting and sample preparation. 
 
Anti-UHRF1 siRNA 
siRNA Targeted sequences 
Human UHRF1 targeting siRNA-1 GCCAUACCCUCUUCGACUA 
Human UHRF1 targeting siRNA-2 GGAACAGUCUUGUGAUCAG 
Human UHRF1 targeting siRNA-3 UGGAGGAGGACGUCAUUUA 
Human UHRF1 targeting siRNA-4 GAACGGCGUGGUCCAGAUG 
Table 3: siRNA anti- UHRF1 targeting sequences. Dharmacon. 
 
 
Anti-Keap-1 siRNA 
siRNA Targeted sequences 
Human Keap-1 targeting siRNA-2 CAGCAGAACUGUACCUGUU 
Human Keap-1 targeting siRNA-4 CGAAUGAUCACAGCAAUGA 
Table 4: siRNA anti-Keap-1 targeting sequences. Dharmacon. 
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3.7 Cell cycle analysis: 
3.7.1 G1 block using double thymidine block: 
We optimized the conditions for this experiment prior to cell treatment, based on the cell cycle 
of each cell line. Using 6 well plates, 15,000 cells / well were maintained in RPMI medium at 37 
⁰C in a 5 % CO2 atmosphere and upon reaching 40 – 50 % confluence were treated with G1 
blocking reagent thymidine at a final concentration of 2 mM (Sigma, T1895-1G) for 19 h, 
followed by washing 3 times using sterile pre-warmed PBS. Two mL of fresh medium was added 
and the cells were transfected with UHRF1-targetting siRNA in selected sets of cells, and then 
incubated for a further 9 h at 37 ⁰C in a 5 % CO2 incubator followed by the addition of a second 
dose of thymidine (2 mM). Cells were incubated for a further 16 h at 37 ⁰C. To release the cells 
from this double block, cells were washed with warm PBS and 2 mL thymidine-free fresh 
medium was added, followed by collection either at different intervals (0, 2, 4, 7, 8, 9 and 11 h) 
or at 24 and 48 h after transfection for lysate preparation and flow cytometry. 
3.7.2 G2/M block using thymidine nocodazole block: 
We optimized the conditions of this experiment prior to cell treatment. Cells were plated and at 
40 % confluence, 100 ng/mL nocodazole was added to the cells and washed after 19 h. At this 
time, cells were transfected with 30 nM UHRF1-targeting or control siRNA and incubated for 
further 3 h. At this time, thymidine (2 mM) was added to the cells and incubated for 16 h and 
collected at 24 h and 48 h for lysate preparation and flow cytometry. The following schematic 
flow chart summarizes cell cycle block treatments (Figure 3-1). 
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Figure 3-1: Schematic flow chart for cell cycle block protocols. 
 
3.7.3 Propidium Iodide (PI) staining protocol: 
The harvested cells were collected, washed with pre-warmed PBS and centrifuged for 5 min at 
100 g as described in [128]. Generally 1 X 105 cells were re-suspended with 100 µL PBS and 
fixed with 1 mL ice cold 70 % ethanol added dropwise to the cells with continuous gentle 
vortexing. Equal number of cells in each sample was kept at 4 ⁰C for at least 16 h before 
staining. On the day of analysis, cell pellets were washed with PBS and stained with 1 mL PI 
buffer (50 µg / mL Sigma), 0.2 % Triton x100 (Sigma) and 1 mg/mL RNase (Sigma, R6513) freshly 
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added. Cells were incubated in the dark for 15 min at room temperature. Then the stained cells 
were subjected to flow cytometry using Guava Easy-Cyte flow cytometer (Guava Technology, 
version 5.3.0.0 and cytosoft PCA96 software) or by BD Biosciences flow cytometer; the best 
detection of the PI staining (535 – 617  nm) using this machine was achieved by using the PE-
Texas Red channel and filter. Results were analysed by Flow Jo software. 
3.8 Cell Proliferation assays: 
Cells (Table 5), were seeded in triplicate in 96 well plates, and at 40 % confluence, cells were 
transfected with 30 nM UHRF1- targeting or control siRNA as described earlier in section (3.6). 
Proliferation was measured 72 h later using the MTS EZ4U kit (Biomedica, Vienna, Austria) 
according to the manufacturer’s instruction and as described in [156]. Briefly, the transfection 
medium was replaced with 100 µL of fresh medium contains substrate (SUB) and activator 
solution (ACT) (1: 10) and the absorbance was measured immediately using a Multiskan EX 
plate reader (Thermo Scientific, UK) at 450 nm and the optimized reading were normalized to 
the reading at 620 nm. Plates were subsequently read every hour up to 3 h. 
Cell line 
Incubation Time (h) 
24 48 72 96 120 
Suit-2 3 1.5 1.5 1 0.5 
MiaPaca-2 4.5 3 3 1.5 1 
CFpac-1 4.5 3 3 1.5 1.5 
Panc-1 6 4.5 4.5 3 3 
Table 5: The initial number of pancreatic cancer cells (n X 10 3) seeded in 96 well plates based 
on the required incubation time for MTS assay. 
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3.9 Apoptotic cell analysis: 
3.9.1 Annexin V Assay: 
Following transfection with UHRF1-targeting and control siRNAs, cell death was analyzed using 
an Annexin V apoptosis Detection kit II from BD Pharmingen according to the manufacturer’s 
instruction and as described in [128]. Approximately, 1 X 106 cells were collected and washed 
with PBS and resuspended in 1 mL of 1X binding buffer and aliquoted into 1 X 105 cells in a 5 mL 
tube (1 mL) and 3 µL of Annexin V and 2 µL of PI were added to the cells and mixed by gentle 
vortexing and incubated in dark for 15 min at room temperature. After incubation, 400 µL of 1X 
binding buffer were added to each tube and analyzed by Cyan flow cytometry within 1 h. To set 
up the flow cytometry, additional control cells, unstained cells, cells stained with FITC Annexin 
V only and cells stained with PI only were used as recommended by the kit’s instruction. Results 
were analyzed by Summit software. 
3.9.2 Caspase 3/7 activity assay: 
Cells were seeded in triplicate in a white walled flat-bottomed 96 well plate at a density of 
5,000 cells per well in 100 µL medium, and either transfected with or without UHRF1-targeting 
siRNA or control siRNA, as described before for 72 h. Transfected cells were either treated with 
or without the general caspase inhibitor ZVAD to a concentration of 30 µM and incubated at 
37⁰C for 36 h. The activity of caspase 3/7 was then measured using the caspase- Glo 3/7 
(Promega, UK) assay kit according to the manufacturer’s instructions and as described in [157]. 
Briefly, 100 µL of caspase reagent was added to the cells and mixed well, followed by 
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incubation for 1 h in the dark at room temperature. Luminescence was then measured using a 
96 well plate luminometer. The results of the luminescent signal are directly proportional to the 
amount of caspase activity present in each sample. 
3.10 Quantification of mRNA levels:  
3.10.1 RNA extraction from cultured cells: 
RNA was extracted from cultured cells using RNeasy kit (QIAgen) according to the 
manufacturer’s instructions and as described in [128]. Briefly, cell lysate was collected by 
adding 200 µL of cell lysis buffer directly to the cultured cells and loaded into a QIAshredder 
spin column placed in a 2 mL collection tube and centrifuged for 2 min at 17,000 g. Cell lysate 
was mixed with 70% ethanol and transferred to RNeasy spin column placed in 2 mL collection 
tube and centrifuged for 15 sec at 10,000 g. The spin column was placed in a clean 2mL 
collection tube and 350 µL of the washing buffer RW1 were added and centrifuged for 15 sec at 
10,000 g. DNase mix (RNase-free DNase set, cat no. 79254) was added directly on to the RNeasy 
silica-membrane, incubated at room temperature for 15 min, washed with 350 µL of RPE buffer 
and centrifuged for 15 sec at 10,000 g. The washing step was repeated twice and an additional 
centrifugation step was undertaken to ensure removal of any excess washing buffer. The RNA 
was collected in a clean 1.5 mL collection tube using RNeasy free water (50-200 µL) and the 
quality and quantity of the RNA were assessed by nano-drop spectrophotometry. 
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3.10.2 cDNA synthesis: 
cDNA synthesis was performed using Promega Improm II reverse transcriptase (RT) kit 
(Promega) following the manufacturer’s instructions and as described in [128]. Approximately 2 
µg of RNA was reverse transcribed by mixing it with the primer mix in a final volume of 20 µL 
and incubating at 70 °C for 5 min followed by addition of 20 µL of RT mix to each sample (final 
volume 40 µL). cDNA was synthesised using the polymerase chain reaction (PCR) according to 
the following cycles:  25°C for 5 min, 42°C for 60 min, 70 °C for 15 min and stored at -80 °C. 
3.10.3 Real-Time PCR (RT-PCR): 
Quantitative real-time PCR (qRT-PCR) was performed as described in [128] to measure the 
mRNA levels of the following targeted genes: KEAP1, NRF2, GCLC, HO-1 and a house keeping 
gene GAPDH. Primers were designed using Primer Express Software (Applied Biosystem, UK) as 
shown in (Table 6). Sybr green master mix (JumpStart Taq, ready mix, 54438-500 RxN) was used 
for qPCR following the manufacturer’s protocol. Briefly, 50 ng of cDNA was mixed with 2X SYBR 
master mix buffer and 1 % of primer dilution mix. The RT-PCR reaction was performed in a 96 
well plate in a total volume of 20 µL per reaction. Samples were incubated for 2 min at 50 ⁰C 
and 10 min at 95 ⁰C, followed by 40 cycles of denaturation at 95 ⁰C for 15 sec, and 
annealing/extension at 60 ⁰C for 1 min. The mRNA quantification was determined by real-time 
PCR (Light Cycler machine from Applied Biosystem (ABI PRISM, 7000 sequence detection 
system) and the outcome data were analyzed using ABI PRISM 7000 SDS software SYBR green 
template mode. The assay was performed in triplicate and GAPDH was used for normalization. 
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Gene Primer and nucleotides sequence 
KEAP1 
Forward  5’ – CAG ATT GGC TGT GTG GAG TT – 3’ 
Reverse  5’ - GCT GTT CGC AGT CGT ACT TG – 3’ 
NRF2 
Forward  5’- GAG AGC CCA GTC TTC ATT GC – 3’ 
Reverse 5’ – TTG GCT TCT GGA CTT GGA AC- 3’ 
GCLC 
Forward  5’- AAC CCA AAC CAT CCT ACC CT - 3’  
Reverse 5’- CTC CTC CTT CCA CTG GGT TG - 3’ 
HO-1 
Forward  5’- GCC AGG TGC TCA AAA AGA TT - 3’ 
Reverse 5’ – CCT GCA ACT CCT CAA AGA GC – 3’ 
GAPDH 
Forward  5’- GGC CTC CAA GGA GTA AGA CC – 3’ 
Reverse 5’ – AGG GGT CTA CAT GGC AAC TG – 3’ 
Table 6. Primers used for RT-PCR. 
3.11 DNA methylation analysis: 
3.11.1 DNA extraction from cultured cells: 
DNA extraction from cultured cells was performed using QIAamp DNA mini kit (Qiagen, cat: 
51304), using the spin protocol, as recommended by the manufacturer. Briefly, harvested cells 
were lysed in 200 µL of lysis buffer (AL) followed by the addition of 20 µL of QIAGEN Protease 
solution. Lysates were then incubated at 56 ⁰C for 10 min and centrifuged at 6,000 g for 1 min 
followed by the addition of 200 µL of absolute ethanol and each sample was vortexed for 15 
sec. Samples were loaded onto the DNeasy mini spin column, centrifuged at 6,000 g for 1 min, 
washed with 500 µL of washing buffer (AW1) and centrifuged at 6,000 g for 5 min. This was 
followed by replacement of the collection tube, addition of 500 µL of washing buffer (AW2) and 
centrifugation at 17,000 g for 3 min. To ensure removal of any remaining buffer, a further 
centrifugation at 17,000 g for 2 min was performed using a clean collection tube. The DNA was 
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eluted from columns using 100 - 200 µL elution buffer (AE) followed by spinning at 17,000 g for 
1 min. The DNA purity and quantity were then assessed by the Nanodrop spectrophotometer 
(Thermo Scientific ND-1000 spectrophotometer). The DNA was stored at -20 ⁰C. 
3.11.2 CT conversion and DNA clean up: 
Approximately 1 µg of DNA (in 20 µL solution volume) was treated with EZ DNA methylation-
Gold Kit (Zymo Research, Orange, CA, USA), reagent preparation, CT conversion and DNA clean 
up procedures were carried out according to the manufacturer's instructions. Briefly, 900 µL of 
dH2O, 300 µL of M-Dilution Buffer and 50 µL M-Dissolving Buffer were mixed together in the CT 
Conversion Reagent tube and allowed to dissolve at room temperature with continuous shaking 
for 10 min. In PCR tubes, 130 µL of the CT conversion reagent were added to 20 µL of the DNA 
and mixed by gentile pipetting. CT conversion reactions were then performed in the thermal 
cycler according to the following incubation periods: 98 ⁰C for 10 min, 64 ⁰C for 150 min and a 
final hold at 4 ⁰C. The treated DNA was then added to Zymo-Spin IC column placed in a 
collection tube containing 600 µL of M-Binding buffer, mixed by gently pipetting and incubated 
for 1 min at room temperature. Samples were then centrifuged at 17,000 g for 1 min and 
columns were washed with 200 µL of M-washing buffer followed by centrifugation at 17,000 g 
for 1 min. Then 400 µL of M-Desulphonation Buffer was added to the column and incubated at 
room temperature for 15 min then centrifuged for 1 min at 17,000 g. Samples were then 
washed twice with 200 µL of M-wash buffer and centrifuged for 2 min after the first wash and 
for 5 min at 17,000 g after the second wash to eliminate any remaining buffer. Columns were 
placed in 1.5 mL micro-centrifuge tubes and 75 µL of pre-warmed (at 50 ⁰C) M-elusion buffer 
was added above the membrane. Treated DNA was collected in 1.5 mL tubes by centrifugation 
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at 17,000 g for 1 min. The bisulphate treated DNA was used as a template in the amplification 
of the promoter regions of KEAP1, CDKN2A, RASSF1, Alu-V and LINE-1 elements by PCR prior to 
pyrosequencing. 
3.11.3 Pyrosequencing Primer Design for KEAP1, CDKN2A, RASSF1, Alu-V and LINE1 elements: 
Primers were designed using Pyromark Assay Design Software by Qiagene (Appendix. 2) and 
synthesized by Eurofins MWG Operon (Ebersberg, Germany). The following table shows the 
primers sequences, product size and number of CpGs included in the analysis for each gene. 
Region Primer’s Primer’s sequence 
Size 
(bp) 
CpGs 
KEAP1a 
Forward 5’ BIO- AAA GGA GAA TAG TAG ATG GTG G -3’ 
87  6 Reverse 5’- TCC CTA TCA CTC TTC CCC -3’ 
Pyrosequencing 5’- CCT TCC CTA TCA CTC TT -3’ 
KEAP1b 
Forward  5’- GGG TAG GTT ATT ATG TTA AGT AGA -3’ 
97  5 Reverse  5’BIO- CCC AAA ACC AAA ATC CTC CA -3’ 
Pyrosequencing  5’- ATTATGATTAAGTAGAGT -3’ 
LINE-1 
Forward 5’BIO- TAG GGA GTG TTA GAT AGT GGG -3’ 
89  7 Reverse  5’- CTT CCC AAA TAA AAC AAT ACC -3’ 
Pyrosequencing 5’- CCA AAT AAA ACA ATA CCT C -3’ 
RASSF1 
Forward 5’- AGT ATA GTA AAG TTG GTT TTT AGA AA -3’ 
117  9 Reverse  5’- BIO-CCC TTC CTT CCC TCC TT -3’ 
Pyrosequencing 5’- AAG TTG GTT TTT AGA AAT A -3’ 
CDKN2A 
Forward 5’- AGG GGT TGG TTG GTT ATT AG -3’ 
75  7 Reverse  5’-BIO- CTA CCT ACT CTC CCC CTC TC -3’ 
Pyrosequencing 5’- GGT TGG TTA TTA GAG GGT -3’ 
ALU-V 
Forward 5’-GAG GTT GAG GTA GGA GAA - 3’ 
85 4 Reverse  5’- BIO-CCC AAA CTA AAA TAC AAT AAC-3’ 
Pyrosequencing 5’- GTT GAG GTA GGA GAA- 3’ 
Table 7 . Primers used for PCR amplification and Pyrosequencing. 
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3.11.4 PCR amplifications: 
PCR reactions were amplified in a final volume 25 µL using Qiagene Hotstart Plus Master Mix Kit 
(Qiagen). Briefly, 200 nM biotinylated primers, 400 nM non-biotinylated primers and 100 ng of 
bisulphite-treated DNA were mixed together and the Applied Biosystems PCR GeneAmp 9700 
Thermocycler was used to amplify the targeted sequences according to the following cycles (All 
PCR programs required initial denaturation and Taq activation 95 ⁰C, 5 min for 1 cycle, Final 
extension: 72 ⁰C for 7 min for 1 cycle and a final hold at 6 ⁰C). The LINE1 PCR programme was 
40 cycles of 94 ⁰C for 30 sec, 58 ⁰C for 45 sec, 72 ⁰C for 45 sec. The Alu-V PCR programme was 
40 cycles of 94 ⁰C for 30 sec, 49 ⁰C for 45 sec, 72 ⁰C for 45 sec. The CDKN2A PCR programme 
was 10 cycles of 94 ⁰C for 30 sec, 56 ⁰C for 40 sec, 72 ⁰C for 30 sec followed by 30 cycles of 94 
⁰C for 30 sec, 55 ⁰C for 30 sec, 72 ⁰C for 30 sec. The RASSF1 PCR program was 40 cycles of 94 ⁰C 
for 30 sec, 50 ⁰C for 30 sec, 72 ⁰C for 30 sec. The KEAP1a and KEAP1b PCR programme was 40 
cycles of 94 ⁰C for 20 sec, 56 ⁰C for 30 sec, 72 ⁰C for 30 sec. The quality and quantity of PCR 
products were confirmed by examining 3 μL of the PCR reactions in 2% agarose gel 
electrophoresis (Fisher Scientific, BP: 1356-500). The DNA was stained with special nucleic acid 
stain (Safe View, Code: NBS-SVI, NB Biologicals) and visualised by a UVP VisionWorks LS 
instrument prior to Pyrosequencing analysis. 
3.11.5 Pyrosequencing assay: 
Pyrosequencing was performed using PSQA kit (Biotage, Uppsala, Sweden) according to the 
manual instruction. Briefly, a mixture of streptavidin sepharose beads and binding buffer 
dilution (Qiagen) were added to the PCR products in 96 well plates and mixed well by vortexing 
for 20 min. Using the PyroMark vacuum station (Figure 3-2A), the filter probes were placed in 
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sterile water for 30 sec and inserted into the 96 well-plate containing the PCR product-
streptavidin mixture for double stranded PCR binding, followed by washing with 70 % ethanol 
for 10 sec and denaturation by 0.2 M NaOH for 20 sec. The single-stranded biotinylated 
template was then washed in washing buffer for 10 sec and released by incubation at 80 °C for 
2 min with continuous shaking in a Pyromark Q96 plate containing sequencing primers followed 
by a cooling down for 2 min and then the plate was placed in the PSQ instrument. The 
PyroMark Q96 cartridge, cartridge 5 (Figure 3-2 B), was loaded with PyroGold Q96 reagents 
(PyroMark Gold Q96, Cat: 972804, Reagents: 5X96), according to pre-run information (PSQ™ 96 
MA software). Each run contained at least 1 internal bisulphate conversion control and a no 
template control. The proportion of DNA methylation at each CpG site was automatically 
calculated by the PSQ™ 96 MA software and given as a percentage. The methylation index for 
each promoter was calculated as the mean value of mC/(mC+C) where C is unmethylated 
cytosine and mC is 5’ methyl-cytosine. The DNA methylation analysis including DNA extraction, 
CT conversion, PCR amplification and pyrosequencing was described in [64].  
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Figure 3-2: The pyrosequencing station. (a). The PyroMark vacuum station. (b). The 
pyrosequencing cartridge. S: substrate. E: enzyme. G, T, A and C: dNTPs. 
 
 
3.12 Cell treatment with siRNA and 5-aza-2’-deoxycytidine: 
In 6 well / plates, 1 X 105 cells were seeded and incubated overnight to achieve 40 % 
confluence. The next day the culture medium was changed and cells were treated with 100 µM 
5-aza-2’-deoxycytidine (Decitabine, Sigma-Aldrich, cat no11390) in the presence or absence of 
UHRF1-targeting or control siRNA for 72 h, with culture medium replaced with fresh medium 
containing 100 µM 5-aza-2’-deoxycytidine every 24 h. Cells were harvested and DNA extraction 
was used in DNA methylation analysis by pyrosequencing in addition to protein analysis. The 
summary of this protocol is shown in Figure 3-3. 
a b
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Figure 3-3: Schematic flow chart of siRNA and 5-aza-deoxycytidine cell treatments. 
 
3.13 Cell treatment with sulforaphane: 
In 6 well / plates, 1 X 105 cells were seeded and incubated overnight to achieve 40 % 
confluence. The next day the culture medium was changed and cells were treated with 5 µM 
sulforaphane in the presence or absence of UHRF1-targeting or control siRNA for 72 h. Cells 
were harvested for protein analysis. 
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3.14 Immunohistochemistry (IHC) for UHRF1 detection: 
IHC conditions were optimized by evaluating two different antigen retrieval buffers (10 mM 
EDTA buffer pH: 8 and Citrate Buffer pH: 6) and demonstrating the best primary antibody 
concentration (1:50, 1:100, 1:200, 1:300) using different cells lines and tissue sections. IHC 
staining was performed on tissue sections and TMA as described in [128]. Generally, the 
sections were incubated in Xylene for 30 min followed by re-hydration in graded ethanol, 100 
%, 90 %, 70 % and 30 %, for 3 min and final 5 min incubation in dH2O. Antigen retrieval was 
obtained by pressure cooking the slides for 5 min in 10 mmol EDTA (pH: 8) following by cooling 
down for 15 min and washing with PBST (0.04 % Tween 20) for 15 min (3 X 5 min). The sections 
were then blocked using peroxidise blocking reagent (Dako, ref: 4006) for 10 min then washed 
with PBST for 15 min (3 X 5 min) and further blocked by 5% filtered Bovine Serum Albumin 
(BSA) for 30 min prior to primary antibody incubation. Anti-UHRF1 (1:200) and KEAP1 (1:100) 
were incubated at 4˚C overnight. The slides were then rinsed in TBST and incubated with a 
relevant conjugated secondary anti-body (Dako) for 1h at room temperature followed by 3 
washes in PBST for 15 min. The staining was developed in DiAminoBenzidine (DAB) reagent 
(Dako, liquid DAB and substrate chromogen system, code: K3467) and washed with PBST and 
counterstained with Haematoxylin (Hematoxylin solution according to Mayer, Sigma, 51275) for 
1 min following washing with running water for 5 min and slides were dehydrated in graded 
ethanol concentrations, 30 %, 70 % and 100 %, for 1 min and a final 3 min in Xylene (Fisher 
Scientific, code: X/0250/17) and mounted with DPX (VWR, ref: 360292F) for microscopic 
examination and scoring. 
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3.15 Immunocytochemistry (ICC) for UHRF1 detection: 
Routinely 10,000 cells / well were seeded and incubated for 24 h at 37˚C in 5 % CO2 using 
chamber slides (154534, lab Tek II, chamber slide with cover, size 8 well, RS glass slide sterile). 
The next day medium was removed and cells were washed with PBS and fixed using 500 µL of 4 
% formalin solution (DPH laboratory supplies, 28794, 295) and incubated at room temperature 
for 30 min. Following washing with 500 µL PBST containing 0.2 % Triton X-100 (Sigma) for 5 min, 
slides were washed with PBS for 3 X 5 min and blocked with peroxidase blocking reagent (Dako, 
ref: 4006) for 10 min. Cells were incubated with primary antibody (1:400) overnight at 4° C, 
then washed with PBST for 3 X 5 min and incubated with secondary antibody at room 
temperature for 1 h, and then washed with PBST for 3 X 5 min. The staining was developed in 
DiAminoBenzidine (DAB) reagent (Dako, liquid DAB and substrate chromogen system, code: 
K3467) followed by 3 washes and counterstained by incubation with with Haematoxylin 
(Hematoxylin solution according to Mayer, Sigma , 51275) for 1 min, washed with running 
water for 5 min, followed by dehydration in a graded ethanol concentrations, 30%, 70% and 
100%, for 1 min in each and a final 3 min in Xylene (Fisher Scientific, code: X/0250/17). The 
chamber boarders were removed and mounted with DPX (DPX mount for microscopy, VWR, 
ref: 360292F) for microscopic examination. 
3.16 Immunofluorescence detection of UHRF1 in pancreatic cancer cells: 
Prior to seeding cells, coverslips were cleaned in ethanol-HCl solution (200 mL 70 % ethnol + 6 
mL concentrated HCl) by soaking for at least 1 h. The coverslips were then rinsed with sterile 
PBS and placed in sterile dishes with 70 % ethanol before being placed in the tissue culture 
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plates. One coverslip was used in each well of a 24 well dish and 70,000 cells / well were seeded 
onto each coverslip and incubated for 24 h. Cells were then washed with PBST and fixed using 
500 µL of 4 % formalin solution for 15 min with gentle shaking at room temperature. Following 
washing with 1 mL PBST containing 0.02% Triton X-100 (Sigma) for 5 min, slides were washed 
with PBST for 3 X 5 min and blocked with 3 % BSA for 20 min. Cells were incubated with UHRF1 
primary antibody (1:400) overnight at 4° C and then washed with PBST for 3 X 5 min and 
incubated with secondary antibody (Donkey anti-mouse Cy3, 715-165-151, Stratech Scientific) 
at room temperature for 1h in the dark. Cells were washed with PBST for 3 X 5 min and 
mounted with 4 µL of the mounting medium (Mowiol 4-88/DABCO with addition of DAPI, 0.1 µg 
/ mL). 
3.17 Scoring and statistical analysis: 
Scoring of the IHC slides was reviewed by 2 pathologists (Prof Fiona Campbell and Dr Timothy 
Andrews). The information recorded for UHRF1 included the nuclear intensity (graded 0 = 
negative, 1 = weak, 2 = moderate and 3 = strong). KEAP1 staining was patchy and granular 
throughout the tumour, therefore scored as either positive or negative. All statistical analyses 
were performed using StatView version 5.0.1 (SAS Institute Inc., Cary, North Carolina). To 
obtain associations between UHRF1 nuclear protein expression and clinical parameters, data 
were cross-tabulated and Fisher’s two-sided exact tests applied or Mann-Whitney U-tests 
performed. Survival analysis was performed using Kaplan-Meier analysis. Spearman’s rank 
correlation was used to correlate the agreement of the nuclear UHRF1 staining percentage 
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between Abcam antibody and Santa Cruz antibodies. Results were considered significant for p 
values < 0.05. 
Generally, the analysis of continuous data that were normally distributed was tested by t-test 
and for data that were not normally distributed a non-parametric test was used such as Mann-
Whitney. The methylation index for each promoter was calculated as the mean value of 
mC/(mC+C) by the PSQ™ 96 MA software and given as a percentage. To assess the association 
between the control siRNA treated cell sets and the UHRF1 depleted cell sets for the DNA 
methylation analysis and between cells treated or not treated with 5-aza-deoxycytidine, an un-
paired t-test was used to analyze methylation values among each group. The caspase 3/7 
activity assay and MTS assay data analysis were performed by un-paired t-test. All statistical 
analyses were performed using StatView version 5.0.1 (SAS Institute Inc., Cary, North Carolina). 
Results were considered significant for p values < 0.05. 
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4 Results and data analysis: 
4.1 Measurement of UHRF1 protein expression levels in different pancreatic cancer cell 
lines and in pancreatic cancer tissue: 
4.1.1 UHRF1 expression in tumour cells: 
UHRF1 is overexpressed in several types of human cancers [55, 56]. A study in this laboratory 
had reported overexpression of UHRF1 in pancreatic cancer but not in normal pancreas [37]. 
However, no descriptive or functional studies of URF1 in this cancer type have been published. 
Therefore, UHRF1 expression in pancreatic tumors and pancreatic cancer cell lines was 
investigated. 
4.1.2 UHRF1 antibody validation: 
Prior to immunohistochemcial staining (IHC) of a pancreatic cancer TMA, two different lysis 
buffers were evaluated for UHRF1 detection and two independent UHRF1 antibodies, from 
Abcam and Santa Cruz. As shown in Figure 4-1 a, western blotting analysis of total protein 
lysate from Panc-1 cells revealed a band of approximately 90 kDa when whole cell lysate was 
prepared using Tris-SDS lysis buffer (the protein was not detectable when RIPA buffer was 
used), equivalent to the expected size for UHRF1. This observation was also made for CFpac-1 
and Suit2 cells, therefore Tris-SDS lysis buffer was used for subsequent experiments. We 
examined for specificity for UHRF1 detection using western blotting as in Figure 4-1 b, MiaPaca-
2 cells using the Abcam antibody showing single band at the expected molecular weight of 
UHRF1. Furthermore, no UHRF1 protein expression was detected in cells treated with specific 
UHRF1-targeting siRNA, where expression was detected in cells treated with the off-target 
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control siRNA. This validation was also made in Suit-2, CFpac-1 and Panc-1. Moreover, as shown 
in Figure 4-1 c, the two independent antibodies successfully detected UHRF1 as confirmed by 
loss of expression in cells treated with the UHRF1 siRNA but not the off-target control siRNA. In 
this study we used 4 different UHRF1-targeting siRNA sequences for UHRF1 depletion, these 
siRNA were evaluated prior to use and all resulted in considerable UHRF1 depletion (Figure 4-1 
d). 
 
 
Figure 4-1. UHRF1 antibody validation (a) UHRF1 detection using the Abcam antibody in Panc-1 
cells using Tris-SDS or RIPA lysis buffer. (b) MiaPaca-2 cells following transfection with control 
siRNAs (C1, C2, C3), Risc-Free or 30 nM UHRF1-targeting siRNAs (1 and 3) for 72 h (n=3). (c) 
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of MiaPaca-2 cells with Risc-Free, control siRNA or 30 nM UHRF1-targeting siRNAs 1 and 3 for 
72 h (n=3). (d) Western blot of UHRF1 following UHRF1 depletion using 4 different UHRF1-
targeting siRNA, 30 nM of each siRNA was used for 72 h (n=2). β-actin was examined in figure 
1a, b and c to verify equal loading of samples. 
 
4.1.3 Validation of UHRF1 antibodies in IHC experiments: 
Thirty-two pancreatic cancer cases provided by the Liverpool CRUK tissue bank were examined 
for UHRF1 expression using the two antibodies (Abcam and Santa Cruz). As shown in Figure 4-2 
a, both antibodies detected nuclear UHRF1 expression as indicated by positive staining. 
Interestingly, staining in the cytoplasmic compartment was also detected using the Abcam 
antibody. Complete absence or very low levels of cytoplasmic UHRF1 was detected with the 
Santa cruz antiboy. The percentages of positive nuclei detected by each antibody was highly 
correlated (Rho=0.89, p<0.001) providing strong evidence of specificity for nuclear UHRF1 
(Figure 4-2 b). Our study therefore focused on nuclear UHRF1 expression. 
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Figure 4-2. Comparison of Abcam and Santa Cruz UHRF1 antibodies. (a) Immunohistochemical 
staining of UHRF1 in 3 independent pancreatic cancer cases. (b) UHRF1 positive nuclei stained 
with Abcam or Santa Cruz antibodies were highly correlated in 32 cases. 
 
4.1.4 UHRF1 protein expression in pancreatic cancer cell lines: 
Pancreatic cancer cell lines, including, MiaPaca-2, CFpac-1, Panc-1, Suit-2 and BxPc-3 were 
examined for UHRF1 protein expression by western blotting analysis. As shown in Figure 4-3, 
the level of UHRF1 expression was variable between the examined cell lines with high levels 
observed in MiaPaca-2 and BxPc-3 cell lines and lower levels observed in CFpac-1 and Panc-1 
cells. 
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Figure 4-3. Western blot analysis of UHRF1 expression in a panel of pancreatic cancer cell 
lines. Whole  cell lysate from pancreatic cancer cell, MiaPaca-2 shows the highest expression of 
UHRF1 while CFpac-1 is the lowest  (n=5). 
 
4.1.5 Evaluation of UHRF1 protein expression in 132 cases of pancreatic cancer: 
 
Immunohistochemical analysis of a pancreatic cancer tissue micro-array (Figure 4-4 a) 
containing 132 cases containing matched duplicate non-malignant and malignant cores 
revealed variable nuclear UHRF1 staining, with 18 patient tumours scored 0 (negative), 36 
scored 1 (weak), 48 scored 2 (moderate) and 30 scored 3 (strong). The scores were based on 
the nuclear intensity of UHRF1 protein staining (Figure 4-4 b). 
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Figure 4-4. Immunohistochemcial analysis of a pancreatic cancer tissue micro-array for the 
detection of UHRF1. (a) TMA slide, the order of the cases in each slide was labeled and cores of 
colon, sarcoma, kidney and liver tissues were used for orientation. (b) UHRF1 expression levels 
in pancreatic cancer tissue scored from 0 to 3 according to the intensity of nuclear UHRF1 
staining. (c) Secondary antibody alone was used as a negative control. 
 
Of note, PanIN lesions were stained for UHRF1 at variable levels. In general for the cases where 
matched tumours and PanIN were available (n=9), the extent of nuclear UHRF1 staining was 
usually greater in the cancer compared to PanIN (Figure 4-5). 
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Figure 4-5. Immunohistochemical analysis of UHRF1 in matched PanIN and tumor. Cases 1 – 4 
show higher nuclear UHRF1 staining in tumours compared to PanINs. Case 5 shows higher 
staining in the PanINs compared to tumours. Generally 9 cases were matched and 8/9 showed 
higher tumour staining compared to PanINs. 
 
Twenty five benign ducts were scored for nuclear UHRF1. Of these, 20 cases (80 %) were 
negative and the remaining 5 cases were positive for nuclear UHRF1 staining (Figure 4-6). 
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Figure 4-6. Immunohistochemical staining of UHRF1 in pancreatic benign ducts. A total 
number of 25 benign ducts were stained and scored as either negative or positive. The majority, 
80% (20/25), were negative and 20% (5/25) were positive.  
 
 
Of note, UHRF1 expressed at high levels in inflammatory cells in the stroma (Figure 4-7), case 1 
and case 2 showing expression of UHRF1 in tissue section of a patient with pancreatic cancer 
and pancreatitis.  UHRF1 expressed in the stroma in approximately 90 % of the positive tumour 
cases. This interesting observation needs further analysis and investigations.   
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Figure 4-7:  Pancreatic cancer sections with positive UHRF1 staining in the stroma. IHC of 
pancreatic cancer sections stained for UHRF1, the brown staining indicating UHRF1 expression, 
the blue staining Haematoxylin (nuclei dye). The black arrows point towards UHRF1-positive 
inflammatory cells. 
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4.1.6 Statistical analysis of immunohistochemically stained TMAs for nuclear UHRF1: 
 
For analysis, nuclear UHRF1 levels were categorized into two groups according to UHRF1 
presence in tissue sections. The first grouping was referred to as negative (score 0) and the 
second grouping was referred to as positive (score of 1, 2, 3). UHRF1 presence was not 
associated with age (< or > 60 years Fisher’s Exact p=0.35), gender (Fisher’s Exact p=0.61), 
lymph node status (Fisher’s Exact p=0.99), grade (poor, moderate, well; Chi Square p=0.09) or 
outcome (Kaplan Meier test, Logrank p=0.98). However, positive expression of UHRF1 was 
associated with larger tumour sizes (> 20 or ≤ 20 mm diameter; Fisher’s Exact p=0.02) as 
summarised in Table 8. 
 
Patient’s parameter P value 
Age (> 60) Fisher’s Exact p=0.35 
Gender Fisher’s Exact p=0.61 
Lymph node status Fisher’s Exact p=0.99 
Grade (poor, moderate, well) Chi Square p=0.09 
Survival Kaplan Meier test, Logrank p=0.98 
Tumour sizes (> 20 or ≤ 20 mm diameter) Fisher’s Exact p=0.02 
Table 8: Statistical analysis of the nuclear UHRF1 (negative or positive) to patient’s 
parameters. UHRF1 staining negative (scored 0) in 18/132 cases while the positive cases 
(scored: 1,2,3) were the majority 86 %. 
 
 
 
Another analysis was used to group cases that either lack UHRF1 expression or show weak 
staining of UHRF1 nuclear indicating low expression in one group (scores 0 or 1), where the 
medium-high (scores 2 or 3) expression of UHRF1 cases were grouped together indicating high 
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expression. UHRF1 expression was not associated with age (< or > 60 years Fisher’s Exact 
p=0.18), gender (Fisher’s Exact p=0.37) or lymph node status (Fisher’s Exact p= > 0.99). On the 
other hand, UHRF1 expression was correlated with tumour grade (poor, moderate, well; Chi 
Square p=0.04), outcome showed a trend toward poor survival with UHRF1 high cases (Figure 
4-8) (Kaplan Meier analysis, Log-rank p=0.07) and high UHRF1 almost had a significant 
correlation with larger tumour sizes (> 20 or ≤ 20 mm diameter; Mann Whitney U, p=0.051). 
The statistical analysis of these groups are summarised in Table 9. 
 
Figure 4-8. Correlation of nuclear UHRF1 expression to patient’s survival. Kaplan Meier 
analysis for 132 pancreatic cancer cases indicating that patients with higher UHRF1 expression 
have poor survival. 
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Data 
n=132 
(%) 
Nuclear UHRF1 expression 
P 
Low 
(scored 0/1) 
(n=54) (%) 
High 
(scored 2/3) 
(n=78) (%) 
Gender 
Male 75 28 47 0.37 
Female 57 26 31 
Tumour 
size 
> 20 104 39 65 0.051 
≤20 28 15 13 
Tumour 
grade 
Well 19 6 13 0.04 
Moderate 71 36 35 
Poor 42 12 30 
Age 
>60 107 44 66 0.18 
≤60 25 14 12 
Lymph 
node 
Yes 106 43 66 > 0.99 
No 20 8 12 
Survival  132 54 78 0.07 
Table 9. Correlation of nuclear UHRF1 expression (low or high) to patient’s clinical data.  
UHRF1 levels were grouped as low (scored 0/1) and high (scored 2/3). 
 
 
4.1.7 Summary and discussion of UHRF1 protein expression in pancreatic cancer cell lines 
and in pancreatic cancer tissue     
 
Little is known about UHRF1 expression in pancreatic cancer. No descriptive or functional studies of 
UHRF1 in this cancer type have been published. Therefore, UHRF1 expression in pancreatic 
tumors and pancreatic cancer cell lines was investigated here. We observed variable nuclear 
UHRF1 staining in 132 pancreatic cancer tissues (negative, low, moderate and high), although 
the majority were positive (86 %). That was also observed in a panel of four pancreatic cancer 
cell lines including MiaPaca-2, CFpac-1, Panc-1 and Suit-2. MiaPaca-2 showed the highest 
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UHRF1 protein expression while CFpac-1 showed the lowest. In tissue sections in the matched 
tumours and PanIN (n=9), the extent of nuclear UHRF1 staining was usually greater in the 
tumour compared to PanIN, whilst the benign ducts were mostly negative for nuclear UHRF1 
staining (80 %). In patient sections, negative UHRF1 expression was statistically correlated with 
tumour size P=0.02.   
In this study, all four pancreatic cancer cells stained positive for UHRF1, with different 
expression levels. The lack of normal pancreatic cells limits our interpretation of UHRF1 
expression in pancreatic cancer cell lines.  Also in tissue sections, normal pancreatic cancer 
specimens were very small in number and that limits our comparison with the tumour sections. 
This is because the normal tissue sections loaded in the TMA were taken from the same 
pancreatic cancer patients from normal lesions surrounding the tumour and in most cases it 
shows early stages of tumour development. 
In pancreatic cancer tissue sections, we evaluated UHRF1 expression using two different UHRF1 
antibodies. The percentages of positive nuclei detected by both antibodies were highly 
correlated, providing strong evidence of specificity for nuclear UHRF1. The Santa Cruz antibody 
was less sensitive for cytoplasmic UHRF1 in pancreatic cancer tissue. Both antibodies are mouse 
monoclonal, but the abcam antibody is raised against amino acids 694-794 of human UHRF1, 
which is at the C-terminal of the protein, while the Santa Cruz antibody is raised against amino 
acids 199-298 of human UHRF1 at the N-terminal of the protein. Our knockdown data support 
the validity of the cytoplasmic staining since depletion of UHRF1 led to loss of cytoplasmic as 
well nuclear staining. Cytoplasmic expression in tumour cells and stromal expression in the 
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inflammatory cells of UHRF1 has not been reported previously. This is an important observation 
that merits additional study in the future. 
In our pancreatic cancer tissue sections, we observed that the presence of UHRF1 was 
associated with larger tumour sizes. This observation did not however translate into a change in 
the outcome for those patients. Although UHRF1 has been associated with poor outcome in a 
variety of tumours [57, 60, 62], in our study no such association was established. 
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4.2 Examination of the functional role of UHRF1 in pancreatic cancer cells: 
4.2.1 UHRF1 is required for optimal growth of pancreatic cancer cells: 
The positive association between UHRF1 expression and tumour size as indicated in the 
previous section 4.1.5.1 suggests that UHRF1 may contribute to pancreatic tumour growth. To 
examine the validity of this hypothesis we attempted to examine the direct effect of depletion 
of UHRF1 protein on pancreatic cancer cell growth (Figure 4-9).  
 
Figure 4-9 . UHRF1 depletion reduced cell proliferation. The MiaPaca-2 cells were either 
transfected with 30 nM UHRF1-targeting siRNA (siRNA1 or siRNA3) or transected with control 
siRNA (C1 siRNA) or left untreated as a control cells (MocK), cell viability was then assessed by 
MTS assay 72h post transfection. Results are a mean of triplicate samples ±SD.   
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 Therefore, the pancreatic cancer cell lines MiaPaca-2, Panc1 and CFpac1 cells were transfected 
with UHRF1 siRNA or off-target control siRNA for 72 h, as shown in Figure 4-10, siRNA-mediated 
down-regulation of UHRF1 expression resulted in clearly diminished cell numbers compared 
with off-target siRNA treatment, as evidenced by phase contrast microscopy and by 
immunocytochemistry. 
 
 
Figure 4-10: Immunocytochemistry of pancreatic cancer cells. Indicated cells were analysed 72 
h post treatment with control siRNA or 30 nM UHRF1-targeting siRNA. UHRF1 depletion was 
associated with pancreatic cancer cell growth. 
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4.2.2 Phenotypic characteristics of pancreatic cancer cells following UHRF1 depletion: 
Given that UHRF1 depletion resulted in diminished cell number (Figure 4-10), we attempted to 
examine phenotypic characteristics of pancreatic cancer cells following the depletion of UHRF1 
expression. MiaPaca-2 cells were transfected with UHRF1-targeting siRNA or an off-target 
siRNA control. As shown in Figure 4-11, UHRF1 depletion resulted in characteristic phenotypic 
changes, where the cells are smaller in size and more rounded in shape compared to control 
cells. This observation was made following every UHRF1 knockdown in all pancreatic cancer cell 
lines used in my thesis, MiaPaca-2, Panc-1, CFpac-1 and Suit-2. 
 
Figure 4-11: UHRF1 is required for pancreatic cancer cell growth. (a) Light microscopy image of 
MiaPaca-2 cells treated with lipofectamine alone (Mock) or with control- or UHRF1-targeting 
siRNAs. (b) Immunocytochemistry (ICC) for UHRF1 expression in MiaPaca-2 cells transfected 
with control- or UHRF1-targeting siRNA. 
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4.2.3 UHRF1 cellular localization, as observed by immunofluorescence analysis: 
 
Our finding of cytoplasmic UHRF1 expression in paraffin embedded pancreatic cancer tissues 
using the abcam antibody (Figure 4-4) was somewhat surprising. Moreover, our ICC analysis of 
cultured pancreatic cancer cells (Figure 4-11) also revealed cytoplasmic staining although 
nuclear expression was more prominent. Therefore, we further investigated UHRF1 expression 
within cells in culture using the technique of immunofluorescence staining. In Panc-1 cells, we 
observed (n=2), as well as in MiaPaca-2 (n=1) and Suit-2 (n=1), both cytoplasmic and nuclear 
UHRF1 expression as demonstrated in Figure 4-12, although cytoplasmic expression was lower 
in level compared to nuclear UHRF1 expression. Treatment with UHRF1-targeting siRNA 
decreased both cytoplasmic and nuclear UHRF1, indicating that the cytoplasmic staining 
observed is also likely to be specific.  
                                                                                                                           Chapter 4: Results and data analysis 
100 
 
 
 
Figure 4-12. Immunofluorescence staining for UHRF1 in Panc-1 cells. Microscopic examination 
of Panc-1 cells stained for UHRF1. The blue staining indicates DAPI, the red staining is UHRF1, 
and the pink represents the merged colours. The non-treated cells were stained with the 
secondary antibody only as a negative control. 
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4.3 UHRF1 expression levels vary according to the stages of the cell cycle: 
4.3.1 UHRF1 expression at the microscopic level: 
Detailed microscopic examination of ICC-stained CFpac-1 cells revealed variation in the level of 
UHRF1 protein expression within different cells from the same population, indeed within the 
same microscopic field (Figure 4-13). Moreover, UHRF1 chromatin binding was also noted as 
indicated by an arrow in Figure 4-13. This observation was made with other cell lines including 
CFpac-1, MaiPaca-2 and Suit-2. 
 
 
Figure 4-13. Microscopic examination of UHRF1 expression in CFpac-1 cells. Different levels of 
UHRF1 protein expression is shown, as is UHRF1 chromatin binding (indicated with an arrow). 
 
 
4.3.2 UHRF1 expression is cell-cycle stage dependent: 
 
Given that previous results (Figure 4-13) obtained from microscopic examination of UHRF1 
expression revealed variable levels of expression between cells, we attempted to determine 
whether these changes in UHRF1 expression reflected different stages of the cell cycle. 
Therefore, the pancreatic cancer cell line CFpac-1 was subjected to a double thymidine block to 
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arrest cells at G1/S of the cell cycle and the level of UHRF1 protein was measured at specified 
times following release from the thymidine block. FACS analysis was used to confirm the double 
thymidine block as well as monitor cell cycle phases after release from the block. UHRF1 
expression was assessed by western blot analysis. The expression levels of cyclin E, cyclin A and 
cyclin B were also examined to confirm different stages of the cell cycle as an internal marker 
for the cell cycle phases (n=1). As shown in Figure 4-14, UHRF1 protein levels were high in cells 
accumulated in S phase (0 h post release), were relatively low as cells proceeded through G1/S 
(2 h and 4 h post release), peaked at 7 h post release as cells reached G2/M and dropped 
significantly at 9 h, as cells exited mitosis (n=1). This observation was also made in MiaPaca-2 
cell (n=1) as following release from double thymidine block UHRF1 expressed at variable levels 
at different time points. 
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Figure 4-14: Variable UHRF1 expression at different time points during the cell cycle. FACS 
analysis (peaks are labeled with color code, red: G1, blue: S and pink: G2/M) and cyclin E, A and 
B measurement by western blotting of CFpac-1 cells/extracts sampled at the indicated time 
points following release from a double thymidine (G1/S) block. Data are representative of n=2. 
 
4.3.3 UHRF1 depletion arrests the cell cycle in G2/M: 
 
To determine whether the peak in UHRF1 at G2/M was functionally important, FACS analysis 
was conducted 72 h post UHRF1-targeting siRNA transfection. Our data suggested an increase 
in the proportion of cells in G2/M. This observation was made in at least 3 independent runs 
using MiaPaca-2 cells. We also noted an increase in the sub-G1 population, pointing towards an 
increase in apoptosis (Figure 4-15). 
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Figure 4-15. FACS analysis of MiaPaca-2 cells following UHRF1 depletion. The top graphs show 
FACS analysis of PI stained cells (peaks are labeled with color code, red: G1, blue: S and pink: 
G2/M) for cells treated with control siRNA and 30 nM UHRF1-targeting siRNA for 72 h. An 
additional peak in the UHRF1 depleted cells was detected; in the figure it is green and labeled 
pre-G1, indicating dead cells. The lower graphs show SSC/FSC plots for PI stained cells treated 
with control siRNA and 30 nM UHRF1-targeting siRNA for 72 h. In the UHRF1 depleted cells, a 
bigger population of dead cells was detected (in the red circle) (n=4).   
 
To examine if the alteration in G2/M and the sub-G1 population was specific to MiaPaca-2 cells, 
we extended the study to additional pancreatic cancer cells, including CFpac-1, Panc-1 and Suit-
2. We observed an increase in the G2/M cell count in each of these cell lines and an 
accumulation in the sub-G1 population in MiaPaca-2, CFpac-1 and Suit-2 cells following UHRF1 
knockdown. An increase in polyploidy cells was also observed in Panc-1 and Suit-2 cells (Figure 
4-16). 
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Figure 4-16. FACS analysis of pancreatic cancer cells transfected with UHRF1-targeting siRNA.  
Cells were treated with control siRNA or 30 nM UHRF1 targeting siRNA for 72 h and stained 
with PI. R5: cells in G1 phase and R6: cells in G2/M phase. A general increase in cell 
accumulation in G2/M phase was observed in UHRF1 depleted cells compared to control siRNA. 
In MiaPaca-2, CFpac-1 and Suit-2 a sub-G1 peak was observed. In Suit-2 and Panc-1 an increase 
in polyploidy cells was observed (n=3).  
 
For further confirmation of G2/M cell arrest following UHRF1 knockdown, Suit-2 cells were 
treated with UHRF1-targeting siRNA, non-targeting siRNA or mock transfected or left untreated 
and synchronised at 2 different points of the cell cycle, G1/S using a double thymidine 
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treatment and G2/M using thymidine/nocodazole treatment (n=2). The cells were treated with 
thymidine for 19 h followed by UHRF1-targeting siRNA transfection then subjected to a second 
block by treatment with either nocodazole or thymidine at a time point of 3 h and 9 h 
respectively, and cells were maintained for 48 h from the time of transfection. UHRF1 depletion 
was confirmed by western blot analysis (Figure 4-17 a). Cell cycle arrest was confirmed by FACS 
analysis (Figure 4-17 b and c). Consistent with our observation that UHRF1 protein expression 
peaked at G2/M phase of the cell cycle (Figure 4-14), cells treated with thymidine/nocodazol, 
which blocks the cells at G2/M (lane 2, Figure 4-17 a) exhibited higher UHRF1 expression than 
cells blocked in G1/S (lane 1, Figure 4-17 a). In Figure 4-17 b cells were examined 24 h following 
release from G1/S. UHRF1-depleted cells showed fewer cells in G1 (200 ± 20 cells), compared to 
control cells in G1 (300 – 400 cells), suggesting fewer UHRF1-depleted cells have completed a 
cell cycle and returned to G1. This may be due to a delay in either S phase and/or in G2/M 
when UHRF1 is depleted. In Figure 4-17 c there was no significant differences in cell count 
between control cells and UHRF1 depleted cells. 
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Figure 4-17. Synchronized Suit-2 cells at 2 different points of the cell cycle using double 
thymidine and thymidine/nocodazole treatment. (a) Western blots showing successful UHRF1 
depletion in the treated Suit-2 cells, (T: double thymidine block only, N: thymidine/nocodazole 
block). β-actin was used as a loading control. (b) FACS analysis for cells treated with double 
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thymidine and either control siRNA or 30 nM UHRF1-targeting siRNA for 48 h. The upper panel 
shows arrested cells, just prior to release from the block, the lower panel shows cells 24 h post 
release and 48 h post transfection with siRNA. The red dot lines showing more cells in G1 in the 
control set compared to UHRF1 depleted cells. (c) FACS analysis for cells treated with 
thymidine/nocodazole and either control siRNA or 30 nM UHRF1-targeting siRNA for 48 h. The 
upper panel shows arrested cells, just prior to release from the block, the lower panel shows 
cells 24 h post release and 48 h post transfection with siRNA. 
 
4.3.4 UHRF1 depletion induces apoptosis in pancreatic cancer cells: 
 
The sub-G1 population observed in UHRF1-depleted cells (Figure 4-16) pointed towards 
apoptosis. To examine directly the effect of UHRF1 depletion on apoptosis, the pancreatic 
cancer cell line Suit-2 was transfected with UHRF1-targeting siRNA, control siRNA and 72 h 
later, subjected to annexin V/PI analysis by FACS. As shown in Figure 4-18, UHRF1 depletion 
results in increased Annexin V/PI staining in cells transfected with UHRF1-targeting siRNA 
compared to control cells (Figure 4-18 a). This observation was also made in CFpac-1 cells. This 
finding was further confirmed for Suit-2 cells by higher levels of Caspase 3/7 activity following 
UHRF1 depletion. The activity of the caspases was higher in UHRF1-depleted cells compared to 
control cells (p= 0.033) (Figure 4-18b). Moreover, the higher caspase 3/7 activity was confirmed 
by the increased cleavage of the pro-caspase 3 protein, as evaluated by western blot analysis of 
caspase 3 after UHRF1 depletion (Figure 4-18 c). Further evidence of apoptosis induction 
following UHRF1 depletion included cyclin E cleavage (Figure 4-18 d) and down-regulation of 
cyclin A and cyclin B (Figure 4-18 e). 
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Figure 4-18. UHRF1 depletion induces apoptosis. (a) Annexin V/PI staining for Suit-2 cells 
treated with control siRNA or 30 nM UHRF1-targeting siRNA for 72 h (n=2) the numbers in each 
square indicating % of cells. (b) Caspase 3/7 activity in Suit-2 cells following indicated 
treatments in triplicate. The caspase 3/7 inhibitor used is 30 µM ZVAD (c) Western blot of Suit-2 
cell extract showing increased levels of cleaved caspase 3 following UHRF1 depletion (n=3). (d) 
Western blots showing cyclin E cleavage. (e) Down-regulation of cyclin A and cyclin B following 
UHRF1 depletion. Data are representative of at least 3 independent experiments and β-actin 
was used as a loading control. 
  
 
4.3.5 Summary and discussion of results following examination of the functional role of 
UHRF1 in pancreatic cancer cells: 
 
In this study we examined the role of UHRF1 in cell cycle regulation in detail. Using pancreatic 
cell synchronisation experiments, we demonstrated variable UHRF1 protein expression at 
different time points in the cell cycle and noted a peak in UHRF1 levels at G2/M of the cell 
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cycle. This is in contrast to the work of Hervouet et al., [81] who showed UHRF1 expression 
levels in glioma cells to be constant in all phases of the cell cycle. UHRF1 knockdown from 
pancreatic cancer cells was accompanied by an accumulation of cells in G2/M. Consistent with 
our findings, Tien et al., [79] also reported cell cycle arrest in G2/M-phase of cancer cells 
following depletion of UHRF1 and described concomitant activation of the DNA damage 
response pathway. In this study, we showed that depletion of UHRF1 in pancreatic cancer cells 
led to a visible loss in cell number, consistent with reports in non-small cell lung cancer [64], 
colorectal cancer [61], and prostate cancer [62]. The growth-inhibitory effect of UHRF1 on the 
pancreatic cancer cell lines tested in this study suggests that UHRF1 is a potentially important 
target for cancer drugs, as noted in other reports [38, 40]. Besides UHRF1’s role in cell cycle 
regulation, UHRF1 contributes to the maintenance of DNA methylation by recruiting DNMT1 to 
hemi-methylated DNA. UHRF1 is an established epigenetic regulator contributing to 
maintenance of DNA methylation [158] and the modification of histones [159].    
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4.4 DNA methylation status in pancreatic cancer: 
UHRF1 is an established epigenetic regulator contributing to maintenance of DNA  methylation 
[158]; it is a key protein in the mechanism which is responsible for recruiting DNMT1 to the 
hemi-methylated DNA. DNA global hypomethylation is a common epigenetic process in cancer 
[105], as is the silencing of TSGs by the hypermethylation of their promoters.  In pancreatic 
cancer CDKN2A [92], RASSF1 [93] are frequently hypermethylated. In this study we examined 
whether loss of UHRF1 protein levels would affect the global DNA methylation level and the 
methylation levels of the frequently methylated TSGs in pancreatic cancer cells. 
 
4.4.1 Global methylation status in pancreatic cancer cells: 
 
In order to examine the effect of UHRF1 protein on the global methylation status in pancreatic 
cancer cells, we first attempted to examine the basal methylation levels of LINE-1 and Alu-V 
elements in pancreatic cancer cell lines by pyrosequencing. We identified the methylation 
status of both LINE-1 and ALu-V in 3 different cell lines (MiaPaca-2, CFpac-1 and Suit-2). The 
mean level of LINE-1 methylation was the highest in MiaPaca-2 cells with a methylation index of 
70.9 % ± 0.34 compared with 58.6 % ± 0.34 and 57.4 % ± 1.2 of CFpac1 and Suit 2 respectively 
(Figure 4-19). These results represent the methylation index of 3 independent experiments. 
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Figure 4-19. The basal DNA methylation status of LINE-1 promoter in pancreatic cancer cells. 
The basal methylation levels of LINE-1 was the highest in MiaPaca-2 cells. 
 
 
The methylation index of Alu-V elements was also estimated via 3 independent runs in 
MiaPaca-2 (46 % ±2.2) and estimated via 2 independent runs in CFpac-1 (40 % ± 1.4) and Suit-2 
(41.5% ± 1.4) (Figure 4-20). 
 
Figure 4-20. The basal DNA methylation status of Alu-V elements in pancreatic cancer cells. 
The average of methylation measured by pyrosequencing. 
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4.4.2  Confirmation of de-methylation of LINE-1 elements in pancreatic cancer by 5-aza-
deoxycytidine: 
 
MiaPaca-2 and Suit 2 cells were treated with the de-methylation drug 5-aza-deoxycytidine for 
48 h and then the methylation status of LINE-1 was examined. A statistically significant 
difference with an approximate 50 % reduction in LINE-1 methylation was observed in the 
examined cell lines (Figure 4-21). 
 
Figure 4-21. The DNA methylation levels of the LINE-1 promoter in cells treated with 5-aza-
deoxycytidine. Methylation was estimated in MiaPaca-2 (n=3) and Suit-2 (n=2). 
 
4.4.3 UHRF1 expression and global methylation in pancreatic cancer cells: 
 
As UHRF1 contributes to the maintenance of DNA methylation, we next examined whether loss 
of UHRF1 protein levels would have an impact on global DNA methylation in pancreatic cancer 
cells. Therefore, we measured differences in the methylation index of LINE-1 and ALu-V 
elements using pyrosequencing following UHRF1 down regulation. In MiaPaca-2, CFpac-1 and 
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30 nM UHRF1-targeting siRNA for 72 h compared to mock or control transfected cells, by 14 % ± 
1.9, 13 % ± 1.6 and 16 % ± 1.7 respectively (Figure 4-22 a). These data were calculated from 6 
independent runs in MiaPaca-2 cells and the observation was made in 3 independent runs in 
CFpac-1 and Suit-2 cells. Alu-V methylation levels were reduced following UHRF1 depletion by 
13.3 % ± 1 in MiaPaca-2 (n=3) and in Suit-2 by 15% (Figure 4-22 b).  UHRF1 depletion was 
confirmed by western blot prior to DNA extraction and pyrosequencing.  
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Figure 4-22. DNA methylation levels in LINE-1 and Alu-V elements following UHRF1 depletion. 
(a) LINE-1 in MiaPaca-2 (n=6), CFpac-2 (n=3) and in Suit-2 (n=3). (b) Alu-V in MiaPaca-2 (n=3) 
and Suit-2 (n=1). The data are presenting UHRF1 depeltion with UHRF1-targeting siRNA3 and 
the same results were obtained (with UHRF1-targeting siRNA1) as each run was performed with 
2 different siRNA controls and 2 different UHRF1-targeting siRNAs. 
 
 
 
 
4.4.4 Evaluation of global DNA methylation following UHRF1 depletion combined with 5-
aza-deoxycytidine treatment: 
 
As shown in Figure 4-22, UHRF1 depletion reduced the global DNA methylation level in 
pancreatic cancer cells. We next examined whether a combination of UHRF1 knockdown and 5-
aza-deoxycytidine treatment would cause an even greater decrease in the global DNA 
methylation in pancreatic cancer than any single treatment. UHRF1 protein was down-
regulated in Miapaca-2 cells by siRNA-mediated depletion followed by 5-aza-deoxycytidine 
treatment and measurement of LINE-1 methylation levels. The experiment was designed to 
include control cells (including non-treated cells and cells treated with non-targeting siRNA), 
cells treated with UHRF1-targeting siRNA only (the effect was previously evaluated (n=6) as 
shown in Figure 4-22 a), cells treated with 5-aza-deoxycytidine only (the effect was previously 
evaluated (n=3) as shown in Figure 4-21) and cells treated with a combination of UHRF1-
targeting siRNA and 5-aza-deoxycytidine. The control cells with either condition, non-treated or 
with non-targeting siRNA treatment showed equal methylation level of LINE-1, for this reason 
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we indicated one control in Figure 4-23 b. Treated cells showed changes to their appearance in 
culture (Figure 4-23 a). In cells treated with 30 nM UHRF1-targeting siRNA for 72 h, a reduction 
in DNA methylation levels of 14 % was observed, while cells treated with 100 nM of 5-aza-
deoxycytidine for 48 h exhibited a reduction in methylation levels of 48 %, the combined 
treatment caused the greatest reduction in methylation levels (63 %) (Figure 4-23 b). 
 
Figure 4-23. UHRF1 depletion combined with 5-aza-deoxycytidine treatment effect on the 
global methylation level. (a) Microscopic examination of MiaPaca-2 cells treated with 5-aza-
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deoxycytidine, UHRF1-targeting siRNA and cells treated with both UHRF1-targeting siRNA and 
5-aza-deoxycytidine. (b) DNA methylation status in each treated cells. 
 
4.4.5 Recovery of UHRF1 following depletion restores global DNA methylation: 
 
Having observed that UHRF1 depletion decreases global DNA methylation, we next asked 
whether restoration of UHRF1 after knockdown was accompanied by a corresponding 
restoration of global DNA methylation. To achieve this, MiaPaca-2 cells were incubated with 
UHRF1-targeting siRNA for 72 hours and UHRF1 levels and LINE-1 promoter methylation status 
measured on the next day and each subsequent day for a total of seven days. We observed that 
the cellular morphology started to recover on day 4 following the UHRF1 knockdown (Figure 
4-24 a). UHRF1 protein was also detected by western blot analysis on day 5 after depletion 
(Figure 4-24 b), and was fully restored by day 6. The time course observation was made in 2 
different cell lines, MiaPaca-2 and Suit-2 (n=3). Global DNA methylation was reduced following 
UHRF1 depletion, as shown previously in Figure 4-22 and continue to decrease with a maximum 
reduction in day 4, then returned to control levels at day 5 (Figure 4-24 c). The methylation 
levels following 5-aza-deoxycytidine treatment alone did not recover in the examined period of 
5 days (Figure 4-24 d). Pointing towards that the influence of the DNA methylation level was 
due to change in UHRF1 expression level.  
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Figure 4-24. UHRF1 influences global DNA methylation. (a) Microscopic examination of 
MiaPaca-2 cells transfected with UHRF1-targeting siRNA for 72 h and 4 days post-knockdown. 
(b) Western blot analysis examining the time course of UHRF1 expression in the days following 
UHRF1 knockdown. β-actin was used as a loading control. (c) and (d) LINE-1 methylation status 
following UHRF1 siRNA (c) and 5-aza-deoxycytidine treatment (d). 
 
 
4.4.6 The methylation status of tumour suppressor genes in pancreatic cancer cells: 
 
The relationship between UHRF1 expression and the hypermethylation of frequently 
methylated CDKN2A [29] and RASSF1 [93] tumour suppressor genes in pancreatic cancer was 
examined. 
We analysed the basal methylation levels of the CDKN2A promoter in CFpac-1 (where the gene 
is wildtype; the gene is fully deleted in MiaPaca-2, and mutated in Suit-2 cells), and the RASSF1 
promoter in MiaPaca-2, CFpac-1 and Suit-2 by Pyrosequencing. The mean methylation index of 
the CDKN2A promoter in CFpac-1 was found to be 93 % ± 2. While the mean basal methylation 
level of RASSF1 in MiaPaca-2 was very high with a value of 94.5 % ± 1.2, the methylation index 
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in CFpac-1 was 17.7 % ± 2.6 and in Suit-2 was 37.4 % ± 3.3 (Figure 4-25). These data were 
calculated as the mean value of 3 independent runs. 
 
Figure 4-25.  The DNA methylation levels of RASSF1 promoter in pancreatic cancer cells. The 
average methylation was calculated from 3 independent runs by pyrosequencing. 
 
4.4.7 The relationship between UHRF1 expression and RASSF1 promoter methylation in 
pancreatic cancer cells: 
 
In MiaPaca-2, CFpac-1 and Suit-2 cells, UHRF1 depletion resulted in decreases in RASSF1 
promoter methylation of 5 % ± 0.4, 81 % ± 3.3 and 17.4 % ± 0.9 respectively (Figure 4-26). These 
data were calculated from 5 independent runs in MiaPaca-2 and 4 independent runs in CFpac-1 
and Suit-2. UHRF1 depletion was confirmed by western blot prior to DNA extraction and 
pyrosequencing. 
 
 
 
0
20
40
60
80
100
120
MiaPaca-2 CFpac-1 Suit-2
RASSF-1
C
p
G
m
e
th
yl
at
io
n
in
d
e
x
                                                                                                                           Chapter 4: Results and data analysis 
122 
 
 
 
 
Figure 4-26. DNA methylation levels of the RASSF1 gene promoter. UHRF1 depletion resulted 
in reduced methylation levels of the RASSF1 gene promoter.  
 
4.4.8 The relationship between UHRF1 depletion and CDKN2A promoter methylation and 
expression in CFpac-1 cells: 
 
The high basal level (93 % ± 6) of CDKN2A promoter methylation in CFpac-1 cells was reduced 
by 21 % ± 6 following UHRF1 knockdown (Figure 4-27 a and b). These data were calculated from 
3 independent runs and each run was performed with 2 different control siRNAs and 2 different 
UHRF1-targeting siRNAs. UHRF1 depletion was confirmed by western blot prior to DNA 
extraction and pyrosequencing. 
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Figure 4-27. DNA methylation status of CDKN2A promoter following UHRF1 depletion. (a) 
Pyrogram of the CDKN2A promoter in CFpac-1 cells transfected with control- or 30 nM UHRF1-
targetting siRNAs for 72 h (n=3). The basal methylation index for CDKN2A was 93 %. In the 
Pyrogram the blue columns indicated the CpGs location and the blue boxes on top of it 
indicated the % of methylation measured at each CpG, the yellow column is the internal quality 
control location, the sequence at the X-axis is the dispensation order and the Y-axis is the light 
intensity measured for each base (b) Mean of triplicate DNA methylation measurements of the 
CDKN2A promoter following treatment with control- or UHRF1-targetting siRNAs. 
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In order to study the relation between UHRF1 and CDKN2A in more depth, we examined the 
expression of the protein product of the CDKN2A gene, P16 following UHRF1 depletion in 
pancreatic cancer cells. UHRF1 depletion alone was not sufficient to cause measurable 
accumulation of P16 protein (Figure 4-28 a). On the other hand, treatment of the cells with the 
demethylation drug 5-aza-deoxycytidine resulted in detectable P16 (Figure 4-28 b). This 
observation was made in at least 4 independent experiments. Moreover, combining UHRF1 
knockdown with 5-aza-deoxycytidine treatment resulted in higher levels of P16 protein 
compared to control siRNA-treated cells (Figure 4-28 c). 
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Figure 4-28. UHRF1 and P16 expression in CFpac-1 cells. (a) Western blot for P16 detection in 
CFpac1 cells following treatment with lipofectamine alone (Mock) or with control- or 30 nM 
UHRF1-targetting siRNAs for 72 h. (b) Western blot analysis and its densitometric analysis for 
cells treated with 100 µM 5-aza-deoxycytidine for 48 h (c) or treated with 100 µM 5-aza-
deoxycytidine for 48 h combined with UHRF1 depletion for 72 h. Western data are 
representative of three independent replicates. β-actin was used as a loading control. The P16 
positive control used is lysate from human embryonic kidney HEK 293 cells. 
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4.4.9 Summary and discussion of UHRF1 role in regulation of methylation status in 
pancreatic cancer cells:   
 
Generally in the panel of pancreatic cancer cells lines (MiaPaca-2, CFpac-1, Panc-1 and Suit-2), 
cells with high UHRF1 protein expression showed a higher level of DNA methylation. 
Therefore, we measured differences in the methylation index of LINE-1 promoter and ALu-V 
elements using pyrosequencing following UHRF1 knockdown. The methylation levels of LINE-1 
promoter were sizably reduced in pancreatic cancer cells following depletion of UHRF1 protein, 
in agreement with a previous report [158]. Moreover, we noted that UHRF1 expression levels 
reflected the basal DNA global methylation of LINE-1 and Alu-V elements; the pancreatic cancer 
cell lines with the highest UHRF1 levels had the highest global methylation levels. Furthermore, 
time course analysis of transient UHRF1 depletion and recovery of UHRF1 protein suggested a 
strong correlation between UHRF1 expression and global DNA methylation. In addition, the 
effect of UHRF1 depletion on LINE-1 promoter methylation was additive to the effect of the de-
methylation agent 5-aza-deoxycytidine treatment. In lung cancer, UHRF1 upregulation was 
significantly correlated with DNA hypermethylation [64], but global DNA hypomethylation of 
LINE-1 and Alu-V elements has also been demonstrated in response to UHRF1 overexpression 
[160]. As a focus for future work, it remains to be seen what effect UHRF1 over-expression can 
have on the global DNA methylation status in pancreatic cancer cells. 
In addition to effects on global methylation, we also observed effects on TSG promoter 
methylation. We showed that the CDKN2A promoter, which is hypermethylated in CFpac-1 
pancreatic cells [92] and in colorectal cancer cells [61] had reduced promoter methylation 
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following UHRF1 knockdown. However, the loss in CDKN2A promoter methylation caused by 
UHRF1 depletion was not sufficient to result in detectable expression of the p16INK4a protein. In 
contrast, UHRF1 depletion from colorectal cancer cells was sufficient to result in detectable 
p16INK4a protein [61]. However, we were able to detect p16INK4a protein when we combined 
UHRF1 depletion with de-methylation treatment using 5-aza-deoxycytidine. From our 
observations, UHRF1 depletion assisted 5-aza-deoxycytidine in activating CDKN2A gene 
expression and restoration of p16INK4a protein expression in pancreatic cancer cells; we suggest 
UHRF1 as a potentially interesting target for cancer therapy to assist reactivation of TSGs that 
have been silenced by promoter hypermethylation. 
Future work should study the correlation between UHRF1 and the methylation status of genes 
of interest in DNA extracted from patients’ tissue with pancreatic cancer tumours and normal 
pancreas. 
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4.5 UHRF1 regulates KEAP1 promoter methylation and activates the KEAP1/NRF2 
pathway: 
 
It has been previously reported by this laboratory that 70 % of PDAC lack KEAP1 expression 
[128]. Therefore we attempted to investigate whether the KEAP1 gene promoter is silenced 
through methylation in pancreatic cancer cells, as has been previously reported for other 
cancers [151-154], and whether UHRF1 contributed to this process. 
4.5.1 Examining KEAP1 protein expression levels in pancreatic cancer cells: 
 
Several pancreatic cancer cell lines, including, MiaPaca-2, CFpac-1, Panc-1 and Suit-2 were 
examined for KEAP1 protein expression by western blotting analysis. As shown in Figure 4-29, 
the level of KEAP1 expression was variable between the examined cell lines with high protein 
expression observed in MiaPaca-2 cells, and lower expression of KEAP1 detected in CFpac-1, 
Panc-1 cells and Suit-2 cells. The western blot analysis of KEAP1 expression showed 2 bands 
(Figure 4-29 a), the top band was at the expected molecular weight of KEAP1 (70 kDa) and at 
the level of the positive control. The positive control is human embryonic kidney HEK 293 cells 
transfected with Keap1-V5. To investigate the specificity of KEAP1 antibody, we treated the 
cells with KEAP1-targeting siRNA. Following KEAP1 knockdown, the protein levels in the lower 
band with molecular weight at 55 kDa, was not changed, while the top band at the expected 
molecular weight of KEAP1 was depleted in the cells treated with KEAP1-targeting siRNA (Figure 
4-29 b). This observation was made in MiaPaca-2 (n=3), Suit-2 (n=3) and CFpac-1 (n=3). As 
evaluation of KEAP1 protein detection, we used 2 different lysis buffers for sample preparation. 
KEAP1 protein was detectable in samples prepared with Tris-SDS only, while samples prepared 
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with RIPA buffer showed only the expression of the lower non-specific band as shown in Figure 
4-29 c.  
 
 
 
Figure 4-29. KEAP1 protein expression in a panel of pancreatic cancer cell lines. (a) The basal 
expression levels of KEAP1 protein. The positive control is human embryonic kidney HEK 293 
cells transfected with KEAP1-V5, the negative control is mock transfected HEK 293 cells. (b) 
KEAP1 expression following KEAP1 depletion in MiaPaca-2 and Suit-2 cells. (c) Western blot for 
KEAP1 protein detection in Suit-2 using 2 different lysis buffers (Tris-SDS and RIPA). β-actin was 
used as a loading control.  
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4.5.2 The DNA methylation status of the KEAP1 promoter in pancreatic cancer cell lines: 
 
Next, we used pyrosequencing to quantify the level of the methylation of the promoters of 
KEAP1 in four cell lines (MiaPaca-2, CFpac-1, Panc-1 and Suit-2). Transcription of the KEAP1 
gene is controlled by 2 transcription start sites (TSS), thus we examined the methylation status 
in the regions upstream of each TSS which is 435 bp away from each point. The region 
upstream of TSS1 was referred to as KEAP1a and the region upstream of TSS2 was referred to 
as KEAP1b (Figure 4-30). 
 
 
Figure 4-30.  Schematic representation of the KEAP1 promoter region. The diagram shows the 
KEAP1 promoters including KEAP1a and KEAP1b regions. The red vertical lines are showing 
locations of the CpGs in the promoter regions. TSS: transcriptional start site. The green dot 
boxes indicated the amplified sequence of each promoter sites that we included in our study. 
 
 
Three of the four cell lines examined showed methylation of the KEAP1a promoter. MiaPaca-2 
cells exhibited a high basal level of KEAP1a promoter methylation (68 %) compared to Suit2 (27 
%) and CFpac-1 (15 %). Methylation of the examined region of the KEAP1a promoter was not 
detected in Panc-1 cells (Figure 4-31). The methylation levels of another region of KEAP1 
promoter, referred to as the KEAP1b promoter. The KEAP1b promoter was not methylated in all 
the examined cell lines. 
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Figure 4-31.  The basal methylation levels of KEAP1 promoters in pancreatic cancer cells. The 
methylation levels of KEAP1a promoter detected in different pancreatic cancer cell lines by 
pyrosequencing (n=3). 
 
 
4.5.3 Depletion of UHRF1 is associated with loss of KEAP1 promoter methylation and up-
regulation of Keap1 protein: 
 
In order to examine the relationship between de-methylation of the KEAP1 promoters and 
Keap1 protein levels, we depleted UHRF1, and extracted DNA and protein for analysis. 
Following DNA extraction and bisulphite treatment, we amplified a region of the KEAP1a 
promoter by PCR (Figure 4-32). 
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Figure 4-32. PCR products for a region of the KEAP1a promoter. The PCR products for the 
KEAP1a promoter, following UHRF1 knockdown or control, were separated on a 2 % agarose 
gel.  
 
Pyrosequencing data indicated that depletion of UHRF1 resulted in a loss of KEAP1a promoter 
methylation in MiaPaca-2, Suit-2 and CFpac-1 cells of 6 %, 42 % and 9 % respectively (Figure 
4-33). 
 
Figure 4-33. UHRF1 depletion reduces the methylation level of KEAP1 promoter in pancreatic 
cancer cells. Mean of triplicate DNA methylation measurements of KEAP1a promoter 
methylation in MiaPaca-2, Suit-2 and CFpac-1 cells following transfection with control- or 
UHRF1-targetting siRNAs. The data are presenting UHRF1-targeting siRNA3 effect; the same 
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results were obtained with UHRF1-targeting siRNA1 as each run included 2 different control 
siRNAs and 2 different UHRF1-targeting siRNA. 
 
In order to study the relationship between UHRF1 and KEAP1a in depth, we examined the 
expression of KEAP1 protein following UHRF1 depletion in pancreatic cancer cells including Mia-
Paca-2, CFpac-1 and Suit-2. UHRF1 depletion was accompanied by a gain in KEAP1 protein level 
in Sui-2 cells as shown in Figure 4-34 a, the same observation was made in MiaPaca-2 and 
CFpac-1 cells. KEAP1 up-regulation was also examined at 3 time points of UHRF1 depletion in 
Suit-2 cells (n=2). We observed significant correlation between UHRF1 loss and KEAP1 up-
regulation at 24, 48 and 72 h (Figure 4-34 b). This observation was also made in CFpac-1 and 
MiaPaca-2 cells (n=2). From these results, UHRF1 depletion affects the expression level of 
KEAP1 as an early event at 24 h following knockdown.  Further analysis based on this 
observation (by another PhD student) showed an increase in KEAP1 mRNA at 24 h following 
UHRF1 depletion.  
 
Figure 4-34. Depletion of UHRF1 in Suit-2 is associated with up-regulation of KEAP1 protein in 
Suit-2 cells. (a) and (b) showing western blot analysis examining UHRF1 and KEAP1 protein 
expression following UHRF1 depletion. β-actin was used as a loading control. 
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We next examined whether altering the methylation of the KEAP1a promoter in a different 
manner could also affect KEAP1 protein levels. We found that treating Suit-2 cells with the de-
methylation drug 5-aza-deoxycytidine (100 µM) resulted in a reduction in KEAP1a promoter 
methylation by 80 % (Figure 4-35 a) and corresponding up-regulation of KEAP1 protein levels 
(Figure 4-35 b). 
 
Figure 4-35. DNA methylation controls KEAP1 expression. (a). The methylation level of KEAP1 
promoter measured by pyrosequencing in Suit2 cells treated with 5-aza-deoxycytidine. (b) 
Western blot analysis showing up-regulation of KEAP1 following treatment in a. β-actin was 
used as a loading control (n=1). 
 
 
To determine whether the increased KEAP1 protein was functionally relevant, Nrf2 protein 
levels were measured. The gain in KEAP1 protein following UHRF1 depletion was concomitant 
with a loss in NRF2 protein level. Moreover, a decrease in the level of NRF2 downstream 
protein Heme Oxygenase 1 (HO-1), was also observed following UHFR-1 knockdown (Figure 
4-36 a). Densitometric measurements showed that the gain of KEAP1 paralleled the reduction 
in NRF2 and HO-1 (Figure 4-36b). 
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Figure 4-36. Immunoblot detection of UHRF1, KEAP1, NRF2 and HO-1 in MiaPaca-2. (a). 
Western blot analysis following UHRF1 depletion, showing gain in KEAP1 protein (n=8), down-
regulation of NRF2 (n=5) and HO-1 (n=4), β-actin was used as a loading control. (b) 
Densitometric analysis for the blots in (a). 
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Additional NRF2 downstream proteins were examined following UHRF1 depletion, namely 
Glutamate-cysteine ligase catalytic subunit (GCLC) and cytochrome P450 2A6 (CYP2A6). UHRF1 
depletion resulted in down-regulation of GCLC (Figure 4-37 a) and CYP2A6 (Figure 4-37 b).  
 
Figure 4-37. Western blot analysis following UHRF1 depletion. (a) Down-regulation of NRF2 
and GCLC (n=3), (b) Down-regulation of CYP2A6 (n=3). β-actin was used as a loading control. 
 
 
Furthermore, preliminary analysis (n=2) showed that the mRNA levels of NRF2 and its 
downstream gene GCLC genes were decreased as well as the mRNA level of the KEAP1 gene 
following UHRF1 depletion for 72 h in Suit-2 cells (Figure 4-38). Further analysis based on this 
observation (by another PhD student) showed an increase in KEAP1 mRNA at 24 h followed by 
reduction at 48 and 72 h after UHRF1 depletion. 
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Figure 4-38. UHRF1 depletion by siRNA for 72 h decreased the mRNA level of the KEAP1, NRF2 
and GCLC genes in Suit-2 cells (n=2). Mean of triplicate mRNA measurements following 
treatment with control- or UHRF1-targetting siRNAs. GAPDH was used a housekeeping gene.  
 
 
 
 
 
 
 
 
0
20
40
60
80
100
120
Control 
siRNA
siRNA1 siRNA3
0
20
40
60
80
100
120
Control 
siRNA
siRNA1 siRNA3
0
20
40
60
80
100
120
Control 
siRNA
siRNA1 siRNA3
0
20
40
60
80
100
120
Control siRNA siRNA1 siRNA3
C
o
n
tr
o
l s
iR
N
A
U
H
R
F1
 s
iR
N
A
1
U
H
R
F1
 s
iR
N
A
3
UHRF1
β -actin
Control 
siRNA
UHRF1-targeting 
trol 
siRNA
UHRF1-targeting 
Control 
siRNA
UHRF1-targeting 
Control 
siRNA
UHRF1-targeting 
m
R
N
A
 (
 %
 r
e
la
ti
ve
 e
xp
re
ss
io
n
)
UHRF1 NRF2
GCLC KEAP1
                                                                                                                           Chapter 4: Results and data analysis 
138 
 
 
 
4.5.4 K-RAS depletion down-regulates UHRF1 protein expression level: 
 
K-RAS activation is the most common genetic change in pancreatic cancer [29]. In pancreatic 
cancer cells, K-RAS depletion causes a decrease in NNF2 mRNA levels and increases reactive 
oxygen species (ROS) which would promote tumourgenesis [118]. We examined the effect of 
UHRF1 depletion on K-RAS, which lies upstream of NRF2 [118]. The expression level of K-RAS 
was unaffected by UHRF1 depletion (Figure 4-39). This observation was made in Suit-2 and 
MiaPaca-2 (n=2). 
 
Figure 4-39. K-RAS expression was unaffected by UHRF1 depletion in Suit-2 cells. Western blot 
analysis of UHRF1 and K-RAS following UHRF1 depletion by 30 nM UHRF1-targeting siRNA for 
72 h (n=2). β-actin was used as a loading control. 
 
We further examined the effect of UHRF1 expression following K-RAS depletion in Suit-2 cells. 
We found that siRNA-mediated K-RAS knockdown resulted in UHRF1 down-regulation (Figure 
4-40). The K-RAS knockdown lysates used in Figure 4-40 were kindly provided by another PhD 
student in our laboratory (Mr Robert Ferguson). 
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Figure 4-40. K-RAS depletion is associated with UHRF1 down regulation in Suit-2 cells. β-actin 
was used as a loading control. 
 
4.5.5 UHRF1 expression in pancreatic tumours is associated with low KEAP1 levels: 
 
Based on the observed inverse relationship between UHRF1 and KEAP1 levels in pancreatic cell 
lines, we sought to determine if this was relevant in patient tumour samples. KEAP1 expression 
was evaluated by IHC for 124 patients in this study, (57/124 patients were previously stained by 
Dr. Taoufik Nedjadi in our laboratory). We stained pancreatic cancer tissue micro-array for 
KEAP1 and scored the cases as either positive or negative, based on the presence of either 
cytoplasmic or extracellular membrane expression of KEAP1 in the tumour cells (Figure 4-41). 
 
Figure 4-41. IHC for KEAP1 in pancreatic cancer tissue. (a) Positive cytoplasmic KEAP1 
expression. (b) Negative KEAP1 expression in the ducts as indicated by the arrows.  
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Of the 124 patients, UHRF1 scores were attributed as follows: 17 scored 0 (negative), 32 scored 
1 (weak), 46 scored 2 (moderate) and 29 scored 3 (strong). For patients with the highest UHRF1 
levels (score 3), the majority (86 %; 25/29) were negative for KEAP1 expression. By contrast, for 
patients lacking UHRF1 expression (score 0), the majority (10/17) expressed KEAP1, with only 
41 % lacking KEAP1 expression. The percentages lacking KEAP1 in the weak and moderate 
UHRF1 expressers were 72 % and 78 % respectively (Figure 4-42). Thus the inverse association 
between UHRF1 level and KEAP1 observed in cell lines was upheld in PDAC tissue (Fisher’s Exact 
p=0.002). 
 
Figure 4-42. UHRF1 expression in pancreatic tumours is associated with low KEAP1 levels. The 
scores attributed for nuclear UHRF1 expression are plotted, grouped according to score, and 
KEAP1 status (white bar = negative; black bar = positive) indicated. 
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4.5.6 UHRF1 expression levels are increased by sulforaphane treatment in pancreatic cancer 
cells: 
 
To gain insight into the physiological role of UHRF1 in the KEAP1/NRF2 pathway, we examined 
the effect of sulforaphane on NRF2 and KEAP1 expression levels. Sulforaphane is known to act 
as an activator of NRF2. We observed an increase in an NRF2 expression in cells treated with 5 
µM sulforaphane for 12 h, and KEAP1 expression was not affected (Figure 4-43 a and b). 
 
Figure 4-43. Western blot analysis for Suit-2 cells treated with sulforaphane. (a) NRF2 
expression and (b) KEAP1 expression. (n=2). 
 
 
We sought to combine sulforaphane treatment with UHRF1 depletion using UHRF1-targeting 
siRNA, but first we asked a question of what effect sulforaphane has on UHRF1 expression. To 
answer this question we treated pancreatic cancer cells with 5 µM sulforaphane for 12 h. We 
found a significant gain in UHRF1 levels following treatment (Figure 4-44 a). This observation 
was made in Suit-2 and MiaPaca-2 cells (n=2). To confirm our observation we studied the effect 
of sulforaphane on UHRF1 expression in a dose-dependent manner. Interestingly we have 
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observed increased levels of UHRF1 as the dose of sulforaphane increased (Figure 4-44 b) in 
Suit-2 cells (n=1). 
 
 
Figure 4-44. Immunoblot detection of UHRF1 in cells treated with sulforaphane. (a) MiaPaca-2 
and Suit-2 cells were treated with 5 µM sulforaphane for 12 h (n=2). (b) UHRF1 expression 
following dose dependent treatment with sulforaphane in Suit-2 cells (n=1). β-actin was used as 
a loading control. 
 
 
Based on this observation, sulforaphane has the opposite effect on UHRF1 expression to UHRF1 
siRNA. Combining the treatments might not have an effect on the expression of UHRF1 or 
NRF2. To examine the effect of this combined treatment, a preliminary study (n=1) was done 
using Suit-2 cells treated with 5 µM sulforaphane for 12 h following UHRF1 depletion for 72 h. 
The results of this experiment were not conclusive, as the levels of KEAP1 or NRF2 were not 
changed following transfecton with UHRF1-targeting siRNA1, while changes were noted when 
the cells were transfected with UHRF1-targeting siRNA3 (Figure 4-45). Of note, the effect of 
sulforaphane was normalised with UHRF1 depletion as the observations in Figure 4-43 and 
Figure 4-45 were examined at the same time. 
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Figure 4-45. Western blot analysis of UHRF1, NRF2 and Keap1 in Suit-2 cells treated with 
sulforaphane and UHRF1-targeting siRNA. (n=1). β-actin was used as a loading control. 
 
4.5.7 KEAP1 depletion reverses the effect of UHRF1 depletion on cell proliferation: 
 
In a preliminary analysis (n=2), we attempted to examine the cell proliferation in cells treated 
with combined depletion of UHRF1 and KEAP1 using MiaPaca-2 cells. UHRF1 depletion alone 
caused a reduction in cell growth by 60 % (Figure 4-46); this observation was previously shown 
in Figure 4-9 while KEAP1 depletion alone resulted in an increase proliferation by approximately 
60 % (Figure 4-46). The double knockdown of UHRF1 and KEAP1 for 72 h resulted in increased 
proliferation by approximately 40 % (Figure 4-46). This observation was made using 3 different 
siRNA combinations. The knockdowns were confirmed by western blot analysis prior to MTS 
analysis.  
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Figure 4-46. MTS analysis of Miapaca-2 cells following combined KEAP1 and UHRF1 depletion.  
Cells were treated with either non-targeting or 30 nM targeting siRNA (UHRF1 or KEAP1 or 
combined) cell viability was then assessed by MTS assay 72h post transfection. Results are a 
mean of triplicate samples ±SD. The western blot analysis for UHRF1 and KEAP1 confirmed 
successful knockdown.  
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4.5.8 Changing cellular location of KEAP1 following UHRF1 knockdown: 
 
In order to examine UHRF1 and KEAP1 protein expression levels and cellular localization in 
pancreatic cancer, we stained fixed cells and probed with anti-KEAP1 antibodies. As previously 
shown, MiaPaca-2, CFpac-1, Panc-1 and Suit-2 cells show nuclear expression of UHRF1 (Figure 
4-10) The expression of KEAP1 is perinuclear and also cytoplasmic in these cells apart from Suit-
2 cells, which interestingly show nuclear expression of KEAP1 in most cases (Figure 4-47 a, b 
and c). When MiaPaca-2 and Suit2 cells were treated with UHRF1-targeting-siRNA, KEAP1 
protein appeared to translocate from the cytoplasm to the plasma membrane (Figure 4-47 a). 
This was less apparent in Suit-2 cells. In Figure 4-47 b Panc-1 cells were weakly stained for 
KEAP1, but some cells show higher expression. CFpac-1 cells showed weak staining for KEAP1 
and cells in mitosis showed elevated expression of KEAP1 (indicated by arrow in Figure 4-47 c). 
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Figure 4-47. ICC of pancreatic cancer cells stained for KEAP1. (a) MiapPaca-2 and Suit-2 cells 
treated with UHRF1-targetting siRNA or control siRNA, stained for KEAP1. (n=2) (b) Non treated 
Panc-1 cells stained for KEAP1. (c) CFpac-1 cells stained for KEAP1 following KEAP1 knockdown. 
 
4.5.9 Summary and discussion of UHRF1 role in KEAP1 promoter methylation regulation and 
activation of the KEAP1/NRF2 pathway: 
 
This is the first study showing that KEAP1 promoter is methylated in pancreatic cancer cells and 
that UHRF1 plays a role in controlling this process. Strong evidence has been presented that 
KEAP1 expression is controlled by its promoter methylation, as the protein level was increased 
following treatment with the demethylation agent 5-aza-deoxycytidine. UHRF1 knockdown 
resulted in loss in KEAP1 promoter methylation and a measurable increase in KEAP1 protein 
expression in pancreatic cancer cells. Although UHRF1 depletion resulted in a small decrease in 
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methylation level in some cell lines, namely MiaPaca-2 and CFpac-1, it had a greater effect at 
the protein level.   
Furthermore, the inverse relationship between UHRF1 and KEAP1 levels observed in cell lines 
was maintained in pancreatic cancer tissue samples, substantiating the notion that UHRF1 
contributes to the control of KEAP1 expression in pancreatic cancer.  
In our study we showed that Panc-1 cells have very low KEAP1 protein expression, although this 
disagrees with the report of Lister et al. [128]. In response to UHRF1 depletion and KEAP1 
upregulation, we observed loss of NRF2 and NRF2-downstream proteins. Thus a model emerges 
in which UHFR1 expression maintains KEAP1 promoter methylation and hence low KEAP1 
levels, which in turn allows NRF2 levels to remain elevated and corresponding NRF2 
downstream proteins to be expressed. However, UHRF1 levels alone were not sufficient to 
explain all KEAP1 expression patterns. This is exemplified by the fact that a small proportion of 
high UHRF1 expressers (14 %) nonetheless express KEAP1, while 41 % of patients lacking UHRF1 
also lacked KEAP1. Thus additional control mechanisms are clearly in place governing the 
KEAP1/NRF2 pathway in pancreatic cancer. The study of the methylation status of the KEAP1 
promoter was limited to pancreatic cancer cell lines. In the future, an expanded study to 
examine KEAP1 promoter methylation in DNA extracted from pancreatic cancer tissues is 
needed to cover the methylation status of KEAP1 promoter in this cancer type. 
NRF2 is an important protein for cell protection, in normal cells sulforaphane is known to 
increase its level and activity. In the case of cancer, a continuous induction of NRF2 by using 
sulforaphane is not recommended during treatment as it increases the cell protection against 
chemotherapy [161]. In our preliminary data, the effect of sulforaphane might be mediated by 
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UHRF1, as the former lost its effect on NRF2 when combined with UHRF1 depletion. More 
investigations regarding this interesting observation are needed to clarify mechanisms. 
The preliminary observation of a possible translocation of KEAP1, from the cytoplasm to the 
plasma membrane, in response to UHRF1 knockdown in pancreatic cancer cells is interesting 
and requires further validation. 
KEAP1 depletion, in agreement with our preliminary observation, and NRF2 activation have 
been reported to promote proliferation of pancreatic cancer cells and resistance to chemo- and 
radiotherapy [128]. NRF2 promotes proliferation and cell growth in other cancers such as 
prostate cancer [155]. Moreover, activating the NRF2 antioxidant program allows cancer cells 
to suppress reactive oxygen species (ROS) [118]. It will be interesting to determine whether 
UHRF1 fits into this scheme. In a genetic model of pancreatic cancer, targeting of the NRF2 
pathway impaired K-RAS (G12D)-induced proliferation and tumourigenesis in vivo [118]. Given 
that NRF2 is possibly regulated by KEAP1-independent mechanisms [119], and our data 
demonstrate a decrease in NRF2 mRNA levels in UHRF1 depleted cells, it is possible that UHRF1 
plays a role in directly regulating NRF2. This would be a focus for future work; it would be 
interesting to examine the effect of UHRF1 depletion or overexpression on NRF2 expression in 
cells negative for KEAP1. 
It has been reported that K-RAS regulates NRF2 expression levels in pancreatic cancer cell lines, 
by decreasing the mRNA levels of NRF2 following K-RAS depletion [118]. In our study we 
showed that K-RAS depletion from pancreatic cancer cells downregulates UHRF1 expression 
levels and upregulates KEAP1 expression. Moreover, UHRF1 depletion from pancreatic cancer 
cells has no effect on K-RAS expression levels. Additionally, in preliminary analysis, we observed 
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that UHRF1 depletion slightly decreased NRF2 mRNA levels in pancreatic cancer cells. Taken 
together, it suggests that K-RAS may act upstream of UHRF1. Accordingly, it is possible that 
UHRF1 mediates the action of K-RAS on NRF2, although this hypothesis requires testing in 
future experiments. 
Our preliminary analysis of the mRNA levels of KEAP1 indicated that they were upregulated 24 
h post-UHRF1 knockdown, and decreased at 48 h and 72 h following UHRF1 depletion. This 
suggests that KEAP1 protein upregulation is an early event following UHRF1 knockdown. We 
observed elevated KEAP1 protein levels at 72 h post UHRF1 knockdown. Further analysis, such 
as the measurement of KEAP1 protein half-life, is required to understand why KEAP1 protein 
levels are high when mRNA levels are low. 
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5 Discussion: 
UHRF1 is an established epigenetic regulator contributing to maintenance of DNA methylation 
[158] and the modification of histones [159]. In this study, we documented UHRF1 expression in 
pancreatic cancer cell lines and pancreatic tumour specimens, in contrast to its infrequent 
expression in benign epithelial ducts. Interestingly, where matched PanINs and tumours were 
available, most cases had stronger UHRF1 expression in tumour cells than in PanINs suggesting 
that UHRF1 protein levels increase during the process of tumourigenesis. UHRF1 may therefore 
facilitate pancreatic cancer cell growth. We observed that depletion of UHRF1 in pancreatic 
cancer cells led to a visible loss in cell number, consistent with reports in non-small cell lung 
cancer [64], colorectal cancer [61], and prostate cancer [62]. Our cell synchronisation 
experiments pointed towards a peak in UHRF1 levels at G2/M of the cell cycle. Consistent with 
our findings, Tien et al. [79] also reported cell cycle arrest in the G2/M-phase of cancer cells 
following depletion of UHRF1 and described concomitant activation of the DNA damage 
response pathway. This is in contrast to the work of Hervouet et al. [81] who showed UHRF1 
expression levels to be constant in all phases of the cell cycle. 
Of note, in our pancreatic cancer tissue sections, we observed that the presence of UHRF1 was 
associated with larger tumour size. This observation did not however translate into a change in 
the outcome for those patients. Although UHRF1 has been associated with poor outcome in a 
variety of tumours [57, 60, 62], in our study no significant association was established. 
Consistent with its role in epigenetic gene silencing, depletion of UHRF1 was accompanied by 
loss of global LINE1 promoter methylation and tumour-specific CDKN2A and RASSF1 promoter 
methylation. Moreover, we showed for the first time that the KEAP1 promoter is methylated in 
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pancreatic cancer cells and that UHRF1 plays a role in controlling this process. The loss in KEAP1 
promoter methylation led to a measurable increase in KEAP1 protein, a phenomenon that was 
not observed with p16INK4a, where UHRF1 depletion alone was not sufficient to result in 
detectable p16INK4a protein. Furthermore, the inverse relationship between UHRF1 and KEAP1 
levels observed in cell lines was maintained in tissue samples, substantiating the notion that 
UHRF1 contributes to the control of KEAP1 expression in pancreatic cancer.  
In response to UHRF1 depletion and KEAP1 upregulation, we reported loss of NRF2 and NRF2-
downstream proteins due to Keap1 regulation. Thus UHFR1 expression maintains KEAP1 
promoter methylation levels, which in turn allows NRF2 levels to remain elevated and 
corresponding NRF2 downstream proteins to be expressed. Here we reported for the first time 
an additional control mechanism for KEAP1/NRF2 pathway in pancreatic cancer (Figure 5-1).  
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Figure 5-1.  Summary of the effect of UHRF1 depletion on the KEAP1/NRF2 pathway and 
its potential impact in pancreatic cancer.  
 
In pancreatic cancer, NRF2 has been reported to promote proliferation of pancreatic cancer 
cells and resistance to chemo- and radiotherapy [128] and the same observation was made in 
prostate cancer [155]. Activating the NRF2 antioxidant program in pancreatic cancer cells of 
genetically modified mice,  also increases cells proliferation and reduces the suppression of the 
reactive oxygen species (ROS) [118].  In the future, it will be interesting to determine whether 
UHRF1 fits into this scheme. NRF2 regulates the inflammatory response and the expression of 
NRF2-dependent genes involved in this process. In a model of acute inflammation, the 
recruitment of macrophages was delayed in Nrf2-deficient mice [162]. It will be interesting to 
determine wither UHRF1 is involved in the inflammatory response, as we have shown the 
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presence of inflammatory cells in high UHRF1 expressing pancreatic cancer tissue sections. 
Pancreatic cancer is highly resistant to chemotherapy [20] and several clinical trials are ongoing 
to improve its treatment [10]. Our data suggests that UHRF1 is a potentially important target 
for pancreatic cancer drugs, due to its multiple effects on pancreatic cancer cells; the growth-
inhibitory effect of UHRF1 depletion on pancreatic cancer cell lines as well as the effect in 
restoring the expression of TSGs that are commonly silenced by their promoter methylation 
(with a greater effect noted when UHRF1 siRNA was combined with the DNMT1 inhibitor 5-aza-
deoxycytidine. Restoring the function of TSGs using epigenetic drugs has shown promise for 
cancer therapy [163-165]. Our novel discovery (upregulation of KEAP1 and downregulation of 
NRF2 by targeting UHRF1 by siRNA in pancreatic cancer cells) makes UHRF1 an interesting drug 
target in pancreatic cancer. It has been reported that targeting NRF2 by siRNA causes a 
decrease in proliferation and an increase in cell resistance to certain drugs [128, 166]. Targeting 
NRF2 alone resulted in a decrease in chemo-resistance to cancer therapy, but this could be a 
double-edged sword due to its ability to protect against cancer initiating insults in normal cells 
[167, 168]. Our results show the dual effect of UHRF1 depletion on the KEAP1/NRF2 pathway. 
This is an important finding, especially as UHRF1 depletion appears to inhibiting NRF2 through 
regulating KEAP1 promoter methylation; this might be an advantage in pancreatic cancer 
treatment, by sensitizing the cells to chemotherapy [166].  
In summary, in this first detailed study of UHRF1 in pancreatic cancer, we provide evidence for 
a role of UHRF1 in pancreatic cancer cell proliferation, and promoter methylation. Finally we 
have uncovered a novel role for UHRF1 in controlling the levels of KEAP1 gene expression and 
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shown that this relationship affects the KEAP1/NRF2 cellular stress pathway, which is known to 
play a role in cancer cell proliferation and chemoresistance. 
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6 Future work: 
In our study we used pancreatic cancer cell lines and pancreatic cancer tissues for detection of 
UHRF1 protein expression. We reported both UHRF1 expression in the nucleus and interestingly 
in the cytoplasm. The cytoplasmic expression of UHRF1 has not previously been reported and it 
will be important to investigate in the future.  
In this study, we evaluated the effect of UHRF1 on DNA methylation status. Our observations 
showed that depletion of UHRF1 resulted in reduced DNA methylation levels when DNA was 
extracted from pancreatic cancer cell lines.  In the future, it will be interesting to expand the 
study and examine the DNA methylation levels and the effect of UHRF1 on global DNA 
methylation (LINE1 and Alu-V) as well as on specific genes (KEAP1, CDKN2A and RASSF1) in DNA 
extracts from patients specimens in order to support our observations.  
This study has shown for the first time that the KEAP1 gene promoter is methylated in 
pancreatic cancer cell lines. Evidence of KEAP1 gene promoter methylation from primary tissue 
samples should be sought. Our novel results showed involvement of UHRF1 in regulating the 
KEAP1/NRF2 pathway in pancreatic cancer, as depletion of UHRF1 resulted in KEAP1 
upregulation in pancreatic cancer cells and tissue samples, thus down-regulating NRF2 and its 
downstream genes. The possibility of a feedback loop with KEAP1 or NRF2 regulating UHRF1 
expression was not completely investigated in this study; evaluating the effect of KEAP1 or 
NRF2 depletion on UHRF1 expression in pancreatic cancer cell is required in the future.  
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It is possible that UHRF1 plays a direct role regulating NRF2 and its downstream effects.  It 
would be interesting to examine the effects of UHRF1 depletion on NRF2 in pancreatic cancer 
cells that lack KEAP1 expression. Our preliminary observation of KEAP1 cellular translocation in 
response to UHRF1 knockdown in pancreatic cancer cells is also interesting and requires further 
validation in future studies.  
We showed that UHRF1 plays an important role in cell proliferation; UHRF1 and NRF2 depletion 
both resulted in reduced cellular proliferation. NRF2 is also known to increase cell resistance to 
chemotherapy.  It would be interesting to determine whether UHRF1 promotes cell 
proliferation and resistance to chemo- and radiotherapy in pancreatic cancer in NRF2-deficient 
cells. Finally, it will also be important to evaluate the correlation of UHRF1 and NRF2 in 
inflammatory cells, as our observations showed increased levels of UHRF1 in inflammatory cells 
within pancreatic tissue samples.  
Generally our results in this thesis are based on UHRF1 depletion in pancreatic cancer cells. 
Thus, the effect of UHRF1 overexpression on cell proliferation, DNA methylation status and the 
KEAP1/NRF2 pathway is an important focal point for our future work. 
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7 Appendices:  
 
7.1 Appendix 1: Database of pancreatic cancer patients used in this study. 
Case 
SURVIVAL 
(Days) 
Censored Age 
Tumor 
size 
Size 
(mm) 
Tumor 
Grade 
Gender 
Lymph 
nodes 
Keap1 
Nuclear 
UHRF1 
1 990 uncensored < 60  NA > 20 Moderate Male yes Negative 3 
2 23 uncensored > 60 20 < 20 Well Male No Negative 3 
3 646 uncensored > 60 20 < 20 Moderate Female No Negative 0 
4 357 uncensored > 60 20 < 20 Poor Male yes Negative 2 
5 297 uncensored > 60 30 > 20 Moderate Male yes Negative 2 
6 122 uncensored < 60 28 > 20 Moderate Male yes Negative 2 
7 1171 uncensored < 60 19 < 20 Poor Male yes Negative 0 
8 923 uncensored > 60 20 < 20 Well Female No Positive 0 
9 2108 uncensored > 60 20 < 20 Moderate Male No Negative 1 
10 2452 uncensored > 60 19 < 20 Moderate Female No Negative 1 
11 356 uncensored > 60 3 < 20 Moderate Female yes Negative 1 
12 279 uncensored < 60 25 > 20 Moderate Male yes Positive 1 
13 98 uncensored > 60 38 > 20 Moderate Female yes Positive 2 
14 127 uncensored < 60 50 > 20 Moderate Female yes  NA 0 
15 792 uncensored > 60 19 < 20 Moderate Male yes Negative 2 
16 525 uncensored < 60 25 > 20 Moderate Male yes Negative 0 
17 315 uncensored > 60 35 > 20 Well Male  NA Negative 2 
18 9 uncensored > 60  NA > 20 Poor Female yes Positive 2 
19 1239 uncensored > 60 40 > 20 Moderate Female yes Positive 0 
20 288 uncensored < 60 15 < 20 Moderate Female yes Positive 0 
21 247 uncensored > 60 22 > 20 Poor Male yes Negative 3 
22 1308 uncensored > 60 30 > 20 Moderate Male No Positive 2 
23 138 uncensored > 60 40 > 20 Moderate Female No Negative 1 
24 489 uncensored < 60 65 > 20 Moderate Female No Negative 3 
25 338 uncensored > 60 70 > 20 Well Female No Positive 2 
26 756 uncensored > 60 50 > 20 Moderate Male  NA Negative 3 
27 153 uncensored < 60 26 > 20 Poor Male yes Negative 1 
28 463 uncensored > 60 30 > 20 Poor Male yes Positive 2 
29 1114 uncensored < 60 25 > 20 Poor Male yes Negative 2 
30 1463 uncensored > 60 35 > 20 Moderate Female yes Positive 3 
31 2442 uncensored < 60 25 > 20 Well Male yes Negative 1 
32 367 uncensored > 60 12 < 20 Poor Female No Negative 2 
33 27 uncensored > 60 70 > 20 Poor Male yes Negative 3 
34 505 uncensored > 60 30 > 20 Poor Male yes Negative 2 
35 31 uncensored > 60 37 > 20 Moderate Female yes Positive 0 
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36 438 uncensored > 60 17 < 20 Moderate Male No Negative 0 
37 444 uncensored > 60 50 > 20 Poor Male yes Negative 2 
38 240 uncensored > 60 35 > 20 Moderate Female yes Negative 1 
39 390 uncensored < 60 25 > 20 Moderate Male yes Negative 3 
40 2698 Censored < 60   > 20 Moderate Female yes Negative 1 
41 158 uncensored > 60 30 > 20 Poor Female yes Negative 3 
42 853 uncensored > 60 35 > 20 Moderate Male yes Negative 3 
43 156 uncensored < 60 40 > 20 Poor Male yes Negative 3 
44 194 uncensored > 60 30 > 20 Poor Male yes Positive 3 
45 480 uncensored > 60 20 < 20 Moderate Male yes Negative 3 
46 647 uncensored < 60 20 < 20 Moderate Male yes Negative 1 
47 314 uncensored > 60 70 > 20 Poor Female yes Negative 0 
48 1704 Censored > 60 15 < 20 Poor Male No Positive 3 
49 433 uncensored > 60 21 > 20 Well Female yes Negative 3 
50 825 uncensored > 60 25 > 20 Poor Female yes Negative 3 
51 688 uncensored > 60 20 < 20 Well Female yes Positive 1 
52 1495 uncensored < 60 9 < 20 Moderate Male yes Negative 1 
53 317 uncensored > 60 35 > 20 Well Male No Negative 2 
54 25 uncensored > 60 38 > 20 Moderate Male yes Negative 3 
55 471 uncensored < 60 30 > 20 Moderate Male yes Positive 1 
56 280 uncensored > 60  NA > 20 Poor Female yes Negative 2 
57 209 uncensored > 60 20 < 20 Poor Male yes Positive 0 
58 175 uncensored > 60 20 < 20 Poor Male yes Negative 2 
59 167 uncensored < 60 65 > 20 Poor Male yes Positive 2 
60 217 uncensored < 60 22 > 20 Moderate Male yes Positive 0 
61 1057 uncensored < 60 8 < 20 Well Female yes Positive 1 
62 150 uncensored > 60 30 > 20 Moderate Male yes Negative 3 
63 810 uncensored > 60 25 > 20 Moderate Female yes Negative 1 
64 651 uncensored > 60 45 > 20 Poor Female yes Positive 1 
65 88 uncensored > 60 60 > 20 Moderate Male yes Negative 3 
66 734 uncensored > 60  NA > 20 Poor Male No Negative 1 
67 337 uncensored > 60 25 > 20 Moderate Female yes Negative 3 
68 98 uncensored > 60 37 > 20 Moderate Female yes Negative 2 
69 242 uncensored > 60 30 > 20 Moderate Male yes Negative 3 
70 196 uncensored > 60  NA > 20 Moderate Male yes Negative 0 
71 768 uncensored > 60 50 > 20 Moderate Male yes Negative 3 
72 432 uncensored > 60 20 < 20 Moderate Female yes Positive 0 
73 492 uncensored > 60 30 > 20 Poor Female yes Positive 2 
74 222 uncensored > 60 30 > 20 Moderate Female yes Positive 3 
75 187 uncensored > 60 30 > 20 Moderate Male yes Positive 1 
76 18 uncensored > 60 40 > 20 Moderate Male yes Negative 2 
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77 340 uncensored > 60 35 > 20 Moderate Male No Negative 2 
78 423 uncensored > 60 33 > 20 Moderate Male yes Negative 1 
79 176 uncensored > 60 45 > 20 Moderate Male yes Negative 2 
80 291 uncensored > 60 20 < 20 Moderate Female yes Negative 2 
81 1934 uncensored > 60 45 > 20 Moderate Female yes Positive 1 
82 1034 uncensored > 60 35 > 20 Moderate Female yes Positive 1 
83 382 uncensored > 60 25 > 20 Well Male yes Negative 3 
84 674 uncensored > 60 30 > 20 Moderate Male yes  NA 1 
85 466 uncensored > 60 33 > 20 Poor Male  NA Negative 2 
86 1059 uncensored < 60 15 < 20 Moderate Female yes Negative 2 
87 776 uncensored > 60 38 > 20 Well Female yes Positive 2 
88 103 uncensored > 60 40 > 20 Poor Male  NA Negative 1 
89 12 uncensored > 60 30 > 20 Well Male  NA Negative 1 
90 310 uncensored > 60 22 > 20 Poor Female  NA Negative 1 
91 807 uncensored > 60 35 > 20 Poor Male No Negative 2 
92 850 uncensored > 60 20 < 20 Moderate Female yes Positive 2 
93 400 uncensored > 60 15 < 20 Moderate Male yes Negative 2 
94 1824 Censored > 60 30 > 20 Moderate Male yes Positive 0 
95 1221 uncensored > 60 40 > 20 Well Female yes Negative 3 
96 2426 Censored > 60 20 < 20 Well Male No Negative 2 
97 531 uncensored > 60 22 > 20 Well Male yes  NA 2 
98 299 uncensored > 60 27 > 20 Moderate Male yes Positive 0 
99 122 uncensored > 60 30 > 20 Poor Female yes Negative 2 
100 300 uncensored < 60 30 > 20 Well Male yes Positive 2 
101 460 uncensored > 60 40 > 20 Moderate Female yes Negative 2 
102 810 uncensored > 60 35 > 20 Moderate Female No Negative 3 
103 289 uncensored < 60 28 > 20 Well Female yes Negative 2 
104 376 uncensored > 60 35 > 20 Moderate Male No Positive 1 
105 1470 Censored > 60 50 > 20 Moderate Male yes Negative 2 
106 15 uncensored > 60 50 > 20 Poor Female yes Negative 2 
107 303 uncensored > 60 45 > 20 Moderate Female yes Negative 1 
108 197 uncensored > 60 35 > 20 Moderate Male yes Negative 2 
109 259 Censored < 60 30 > 20 Moderate Female No Negative 3 
110 475 uncensored > 60 24 > 20 Well Female yes Negative 1 
111 131 uncensored > 60 25 > 20 Poor Male yes Negative 2 
112 340 uncensored > 60 50 > 20 Moderate Female yes Negative 2 
113 903 uncensored > 60 17 < 20 Moderate Female yes Negative 0 
114 575 uncensored < 60 40 > 20 Moderate Male yes Negative 1 
115 253 uncensored > 60 65 > 20 Poor Male yes Negative 2 
116 216 uncensored > 60 43 > 20 Moderate Male yes Positive 0 
117 309 uncensored > 60 40 > 20 Moderate Female yes  NA 3 
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118 86 uncensored > 60 40 > 20 Poor Female yes Negative 1 
119 367 uncensored > 60 33 > 20 Well Female yes Negative 2 
120 584 Censored > 60 40 > 20 Moderate Male yes Negative 3 
121 100 uncensored > 60 45 > 20 Poor Female yes Negative 2 
122 240 uncensored > 60 45 > 20 Poor Male yes Negative 1 
123 110 Censored > 60 25 > 20 Poor Female yes Negative 1 
124 389 uncensored < 60 27 > 20 Poor Female yes Negative 2 
125 94 uncensored > 60 45 > 20 Poor Male yes Negative 2 
126 310 uncensored > 60 30 > 20 Moderate Male yes Negative 1 
127 76 uncensored > 60 38 > 20 Poor Male yes Negative 3 
128 33 uncensored > 60 6 < 20 Poor Male yes Negative 2 
129 418 uncensored > 60 30 > 20 Moderate Female yes  NA 1 
130 262 uncensored > 60 30 > 20 Poor Male yes  NA 1 
131 1824 Censored > 60 30 > 20 Moderate Male yes  NA 1 
132 645 Censored > 60 30 > 20 Poor Female yes  NA 2 
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7.2 Appendix 2: Primer design 
Primer designs of the targeted sequence in the promoter regions of the LINE1, RASSF1, 
CDKN2A, KEAP1a and KEAP1b generated using primer assay design from Qiagen.  
 
 
LINE-1
RASSF-1
CDKN2A
KEAP1 a
KEAP1 b
Forward primers
Sequencing primer
Reverse primer
Biotinylated primer
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7.3 Appendix 3 :Pyrogram of LINE-1, RASSF1 and Alu-V. 
 
LINE1
MiaPaca-2
CFpac-1
Control siRNA
UHRF1 siRNA
Control siRNA
UHRF1 siRNA
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Suit-2
Control siRNA
LINE-1
UHRF1 siRNA
RASSF1
MiaPaca-2Control siRNA
UHRF1 siRNA
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CFpac-1
Control siRNA
UHRF1 siRNA
Suit-2Control siRNA
RASSF1
UHRF1 siRNA
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Alu-PV MiaPaca-2
Suit-2
Control siRNA
UHRF1 siRNA
Control siRNA
UHRF1 siRNA
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